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Introduction and methods 
Asymmetric dimethylarginine (ADMA) is a potent endogenous competitive 
inhibitor of nitric oxide synthases, which has attracted considerable attention 
as a marker and mediator of atherosclerotic disease and as a potential 
mediator of multiple organ failure in critical illness due to endothelial 
dysfunction.  However, data regarding basic aspects of its biology such as 
biological variation and its response to acute inflammation are lacking.  
Moreover, significant methodological variability has been a barrier to collating 
the burgeoning data available.  Therefore, this thesis describes the 
development and validation of a reliable assay for measurement of ADMA and 
related compounds in plasma, urine and other biological fluids based on 
isocratic reverse phase high performance liquid chromatography (HPLC).   This 
method was used to determine the biological variation of ADMA in human 
plasma, and its response to acute inflammation using a model of elective knee 
arthroplasty.  Further HPLC methods for measurement of dimethylamine 
(DMA), the main metabolite of ADMA, and nitrate were developed and used to 
determine excretion of these compounds in acute inflammation to 
complement the observed changes in plasma ADMA concentration. 
 
Results 
Complete chromatographic separation of arginine, homoarginine, 
monomethyl-arginine, ADMA and its structural isomer SDMA was achieved, 
permitting their accurate quantification using a novel, non-endogenous, 
internal standard.  The intra-individual biological variation of ADMA was found 
to be low at 7.4%, imposing a tight imprecision goal for analytical methods.  
Plasma ADMA concentration decreases rapidly during the acute inflammatory 
response, with a median decrease of around 30%, and a significant change 
already evident as little as 12 hours following the onset of inflammation.  No 
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similar change was seen in the concentration of the closely related compound 
SDMA.  No significant increase in the urine excretion of DMA was noted during 
the early phase of the response, with a significant increase seen 5 days 
following the insult by which point the plasma ADMA concentration had 
returned to baseline levels.  A small, but significant, decrease in nitrate 
excretion during the inflammatory response was seen, mirroring the observed 
changes in plasma ADMA. 
 
Conclusion 
The low biological variation of ADMA suggests physiological regulation.  The 
rapid and significant decrease in plasma concentration during inflammation 
does not appear due to increased catabolism, but rather is more likely to 
represent increased cellular partitioning.  This may be associated with an 
impairment in NOS activity.  It is unclear whether this is of pathological 
significance, or represents a physiological response to regulate NO production 
in inflammation.  Further study is warranted in relevant models, particularly 
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1.1  Arginine and its endogenous methylated derivatives 
 
1.1.1 Biochemistry of arginine 
 
Arginine is a semi-essential amino acid, and is characterised by a guanidino 
group on its side-chain.  With a pKa of around 12.5 the guanidino group is 
protonated at physiological pH, giving the molecule a net positive charge.  
This renders arginine important at the surface of proteins, with a role in 
receptor-ligand interactions.  It is also an important role in several metabolic 
pathways, including the urea cycle, as a substrate for gluconeogenesis, and, 
crucially, as the substrate for nitric oxide (NO) production by nitric oxide 
synthases (NOS). 
 
1.1.2 Methylated derivatives of arginine 
 
In common with other amino acids arginine is subject to various post-
translational modifications which contribute to the functionality of different 
proteins.  One or two methyl groups can be added to the nitrogen atoms of 
the guanidino group to yield mono- and dimethylarginines.  Dimethylarginines 
had been identified in human urine in the early 1970s1, although it was about 
two decades before their potential importance in human physiology was 
realised2.  The chemical structures of arginine, monomethylarginine (MMA), 
asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) 












1.1.3 Synthesis of methylarginines 
 
Endogenous methylarginines are synthesised by a group of enzymes called 
protein arginine methyltransferases (PRMT), which methylate arginine 
residues within proteins3,4.  In mammals there are two main types, both 
utilising S-adenosyl methionine as a methyl group donor.  Type 1 PRMTs have 
a fairly wide range of substrate proteins, including histones and non-histone 
nuclear proteins, and largely produce ADMA4.  Type 2 PRMTs  appear specific 
to myelin basic protein, and largely produce SDMA, a structural isomer of 
ADMA4.  Both PRMTs produce MMA.  Methylated proteins interact with nucleic 
acids and thus protein methylation has important roles in processes like 
transcription and the epigenetic regulation of gene expression.  Free MMA, 
ADMA and SDMA appear on degradation of the proteins containing them.  It is 
generally felt that arginine methylation is an irreversible process.  There is 
evidence that the activity of type 1 PRMTs can be increased by native and 
oxidised low density lipoproteins (LDL)5, increased shear stress6 and anti-
double stranded DNA antibodies7; this suggests that in certain pathological 
states increased PRMT activity could contribute to increased ADMA 
concentrations.  It has been estimated that humans generate about 300 µmol 
of ADMA per day8. 
 
1.2 Clearance of endogenous methylarginines 
 
1.2.1 Catabolism of ADMA by dimethylarginine dimethylaminohydrolase 
(DDAH) 
 
Earlier studies in rabbits had suggested the presence of a metabolic pathway 
for elimination of ADMA many years before the enzymes responsible were first 
identified9.  It appears that approximately one-sixth of the ADMA generated in 
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humans is excreted unchanged into urine2,8, with the majority metabolised by 
DDAH8,10-12 yielding citrulline and dimethylamine10. The metabolic activity of 
DDAH is dependent on a cysteine residue at its catalytic site12.   It has also 
been demonstrated that its molecular structure excludes SDMA as a substrate, 
meaning DDAH is specific for ADMA12.  SDMA, therefore, appears to undergo 
clearance predominantly by renal excretion, as suggested by its significant 
net renal extraction and the strong correlation of plasma SDMA and creatinine 
concentrations13.  The Michaelis constant (Km) of DDAH for ADMA is 
approximately 180 µM, which is many times greater than typical ADMA 
concentrations in humans10.  This means that DDAH should be operating within 
the linear part of its substrate-velocity curve, theoretically permitting a tight 
regulatory influence of DDAH activity on ADMA concentration. 
 
1.2.2 Isoforms and distribution of DDAH 
 
There are two isoforms of DDAH.  DDAH-1 is expressed widely in tissues 
expressing neuronal NOS, especially in the liver and renal cortex, but also in 
diverse tissues such as the pancreas and macrophages11,14.  The liver and 
kidney are therefore quantitatively important sites of ADMA catabolism, 
studies in rats demonstrating fractional excretions of around 30% and 35% 
respectively15,16.  In humans the net renal excretion has been calculated as 
16.2%13.  The importance of the liver in ADMA catabolism is further supported 
by studies showing increased concentrations following major hepatectomy17, 
the strong influence of hepatic dysfunction on ADMA concentrations in 
critically ill patients18, and reductions in ADMA concentration following liver 
transplantation19. 
 
DDAH-2 is expressed widely in foetal tissues, becoming fairly selective for 
sites expressing endothelial NOS (eNOS) in adults14,20.  It thus predominates in 
the vascular endothelium and cardiovascular system, but is also expressed in 
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immune tissues expressing inducible NOS (iNOS)20.  While DDAH-1 has also 
been demonstrated in the endothelium, DDAH-2 appears to exceed it by a 
factor of 10 or more, suggesting that DDAH-2 is the isoform of major 
importance in blood vessels14.  DDAH-2 is also found in the kidney, specifically 
within its vasculature, and may be involved in NO-mediated homeostatic 
responses in that organ21. 
 
Targeted silencing of DDAH isoforms by small interference RNAs has generated 
data suggesting differential roles of the two isoforms14.  DDAH-1 silencing is 
associated with increased plasma ADMA concentration, but little effect on 
blood vessel NO responses.  In contrast DDAH-2 silencing is associated with 
impaired blood vessel responses, but no significant effect on circulating ADMA 
conentrations14.  DDAH-1 has, therefore, been dubbed the “guardian of 
circulating ADMA” concentrations20.    However, more recent work using a 
DDAH-1 knockout mouse showed increased plasma and tissue concentrations 
of ADMA, with raised blood pressure, and no measurable DDAH activity22.  The 
authors of this study speculate that DDAH-1 is the predominant enzyme for 
ADMA catabolism, and that the role of DDAH-2 is doubtful22.  It will be 
important to further delineate isoform-specific roles of DDAH. 
 
Polymorphisms in the genes encoding DDAH enzymes have been increasingly 
studied because of their potential effects on ADMA concentrations, and 
certain polymorphisms have been implicated in cardiovascular risk23, and in 







1.3 Pathophysiological roles of DDAH and ADMA in endothelial dysfunction 
 
1.3.1 DDAH activity impairment in oxidative stress 
 
The critical role of DDAH in vascular health arose from observations using a 
pharmacological DDAH inhibitor which induced a gradual vasoconstriction in 
isolated vascular segments that was reversed by the addition of arginine25.  
This suggested that ADMA was produced continuously, DDAH acting to prevent 
its accumulation.  Furthermore, transgenic mice over-expressing DDAH-1 
demonstrated a 50% reduction in plasma ADMA concentration compared with 
wild type, associated with increased urinary nitrate and a 15 mmHg reduction 
in systolic blood pressure26.  DDAH over-expression is also associated with 
protection from exogenous ADMA in the cerebral circulation27, and DDAH-2 
over-expression ameliorates vascular injury in response to ADMA infusion in 
mice28.   
 
The cysteine residue at the catalytic site of DDAH is susceptible to oxidative 
stress with attenuation of enzyme activity12, thus providing a link between 
vascular risk factors, oxidative stress, raised ADMA concentration and 
endothelial dysfunction.  Such an effect has been demonstrated with oxidised 
LDL and tumour necrosis factor α (TNFα)29, associated with increased ADMA.  
Similar effects have seen with hyperglycaemia30, hyperhomocystinaemia31 and 
cigarette smoke extract32.  Furthermore, eNOS uncoupling by ADMA increases 
production of superoxide with the potential to further impair DDAH and 
increase ADMA even further in a perpetuating cycle33.  DDAH can also be 
inhibited by nitrosylation and in states of excess NO production, especially by 
iNOS, may provide a mechanism through which accumulating ADMA acts as a 
“brake” on harmfully excessive levels of NO production34.  Interactions 
between oxidative stress, DDAH, ADMA and NOS are summarised and 
illustrated diagrammatically in figure 1.2. 
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Figure 1.2:  Interactions between oxidative stress, DDAH activity, ADMA 
and NOS 
 
1.3.2 ADMA in NOS inhibition and endothelial dysfunction 
 
The discovery of NO as the endothelial-derived relaxing factor was a major 
breakthrough in the understanding of the vascular endothelium and its 
dysregulation in disease35.  It has several other functions including inhibition 
of processes involved in atherosclerosis such as smooth muscle cell 
proliferation, platelet aggregation and adhesion, and monocyte adhesion; it 
can thus be described as an anti-atherogenic molecule36.  It is also part of the 
immune response, and is produced in large quantities in response to sepsis 
and inflammation37.  It is synthesised from arginine by NOS38, of which there 
are endothelial, inducible and neuronal isoforms39. 
 
ADMA and MMA are competitive inhibitors of all NOS isoforms2,5,40,41, although 
attention has focussed almost entirely on ADMA as the predominant NOS 
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inhibitor in human plasma.  The seminal work of Vallance showed that intra-
arterial infusion of ADMA into healthy volunteers caused a dose-dependent 
decrease in forearm blood flow, an effect that could be partially offset by 
infusion of arginine2.  In the same study ADMA injections into guinea pigs 
resulted in a 15% increase in systolic blood pressure at an ADMA concentration 
about 9 times that at baseline (9.8 µmol/L).  In healthy human males 
intravenous infusion of ADMA to generate concentrations up to 3 times normal 
raised systemic vascular resistance by approximately 24% and impaired the 
cardiac response to exercise8.  A similar study showed a 14 % decrease in 
cardiac output42.  ADMA also appears to reduce renal perfusion and sodium 
excretion and increase blood pressure42,43 and inhibit flow/shear-stress-
induced vasodilatation in isolated arterioles44.   
 
The experimental studies described in the foregoing paragraph involve plasma 
concentrations greater than those seen in health and many disease states 
(e.g. 2.60 – 5.31 µmol/L compared with a “normal” value of around 0.5 
µmol/L45).  However, observational studies seem to confirm the in vitro 
relevance of ADMA, with a significant inverse correlation shown between 
plasma ADMA concentration and brachial flow-mediated dilatation in over 
2,000 healthy young adults46.  Similar associations have been demonstrated in 
individuals with hypercholesterolaemia47, type 2 diabetes mellitus48 and 
chronic kidney disease49.  Furthermore, plasma ADMA concentration was 
significantly associated with progression of carotid intima-media thickness in 
individuals without overt cardiovascular disease50. 
 
Another relevant factor in the interpretation of plasma ADMA concentrations 
is the fact that intracellular concentrations can be approximately 5 – 10 times 
that found in plasma, with endothelial cells actively able to take up ADMA and 
concentrate it intracellularly51.  Given that the inhibitor constant (Ki) of ADMA 
on eNOS is around 0.9 µmol/L, it is clear that a modest increase in plasma 
ADMA concentration could have a significant effect on NO production51.  
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Further work is needed to elucidate the relationship of intra- and 
extracellular concentrations of methylarginines in vivo. 
Although SDMA has no direct effect on NOS, it is able to compete with 
arginine for transport via cationic amino acid transporters (CAT), thereby 
potentially reducing substrate availability for NO synthesis52,53.  In cultured 
endothelial cells, SDMA reduced NO synthesis in a dose-dependent fashion, an 
effect that was reversed by arginine supplementation53. 
 
1.3.3  Associations of ADMA with vascular risk factors 
 
There has been much work seeking associations with traditional and novel 
cardiovascular risk factors as part of the underlying hypothesis that, through 
NOS inhibition, ADMA could be a mediator of endothelial dysfunction.   
 
1.3.3.1  Hypercholesterolaemia 
The evidence in hypercholesterolaemia is inconsistent.  Diet-induced 
hypercholesterolaemic rabbits and monkeys have an approximately 2-fold 
increase in ADMA concentration54,55, and associations have also been 
demonstrated in humans47,56,57.  Other human studies have failed to replicate 
this link58,59, although one of these studies included only individuals with total 
cholesterol < 4.6 mmol/L58  and in the other more than 50% of participants 
were already taking lipid lowering drugs59.  Lowering of plasma ADMA  
concentration on statin treatment has also been an inconsistent finding, with 
studies showing reductions with rosuvastatin and fluvastatin60,61, but no 
changes in other studies despite large reductions in cholesterol62-66.  It has 
also been shown that higher ADMA concentrations are associated with a 
reduced responsiveness in terms of endothelial function to statin 
treatment67,68, suggesting that high ADMA concentrations might be able to 
block the pleiotropic effects of statins, which include up-regulation of eNOS69.   
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1.3.3.2  Obesity, insulin resistance and diabetes mellitus 
Hyperglycaemia seems to result in oxidative stress which can impair DDAH 
activity in human cells30, and plasma ADMA concentrations are raised in 
individuals with impaired glucose tolerance70-72, and are associated with 
impaired myocardial tissue perfusion in this context72.  In subjects undergoing 
angiography, ADMA was found to strongly predict glycaemic category (normal, 
impaired and diabetes)73, and in women with previous gestational diabetes 
was found to predict the development of glucose intolerance with an adjusted 
hazard ratio of 3.94 (1.16 – 13.37) for an ADMA concentration above the 
median during 3 years of follow up74.  In obese women, ADMA concentrations 
are higher in those with associated insulin resistance, and in these individuals 
weight loss through caloric restriction decreases ADMA concentration and 
improves insulin sensitivity75.  Weight reduction surgery in morbidly obese 
women is also associated with decreases in plasma ADMA76.  In neither of 
these studies, however, was weight independently associated with ADMA as 
such75,76; rather it appears that the metabolic abnormalities that can develop 
in the setting of obesity are what influence the ADMA concentration, and the 
reduction in ADMA concentration following weight loss occurs in line with 
improvements in parameters of insulin sensitivity rather than the measured 
weight76.  In patients with diabetes mellitus plasma ADMA concentration is 
associated with albuminuria and microangipathy77, and independently and 
strongly predicts the development of retinopathy78 and the progression of 
nephropathy79. 
 
As in hypercholesterolaemia, the effect of pharmacological treatment on 
ADMA is also variable.  In type 2 diabetes, 3 months of treatment with 
metformin decreased plasma ADMA concentration by about 30%80, and similar 
reductions have been seen in women with polycystic ovarian syndrome and 
insulin resistance81.  Peroxisome proliferator-activated receptor gamma 
(PPARγ )agonists have been shown to reduce plasma ADMA and improve 
endothelial function in subjects with type 2 diabetes71,82, although negative 
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results with this therapy have also been reported83.  DDAH-2 contains a PPARγ 
binding site in the promoter region, and this provides a possible mechanism 
for the effect of these drugs84.  Lastly, intensive glucose control, irrespective 
of how it is achieved, reduces plasma ADMA concentration and improves 
vascular function, possibly through anti-cytokine and anti-atherogenic 
effects85. 
 
1.3.3.3  Hypertension 
The crucial role of NO on vascular tone and function predicts a role for ADMA 
in hypertension.  DDAH-1 knockout mice demonstrate a significant increase in 
plasma ADMA concentration and blood pressure22,86,87, although, intriguingly 
data do not suggest that  DDAH-2 is as important, at least under basal 
conditions28,88.  In humans with hypertension, plasma ADMA concentrations are 
increased compared with healthy controls and are related to markers of 
endothelial dysfunction89-91 and are associated with mean blood pressure in 
healthy individuals70.  Moreover, ADMA infusion into healthy volunteers 
reduced renal blood flow, increased salt retention and raised systemic blood 
pressure42.  Interestingly, plasma ADMA concentration is also raised compared 
with controls in subjects with so-called “white coat hypertension”, perhaps 
suggesting that this is not an entirely benign phenomenon92.  It has also been 
shown that in healthy young men, black Africans have significantly reduced 
NO and flow-mediated dilatation compared with white Europeans, and this is 
independently associated with ADMA concentration93.  It is intriguing to think 
that this could underlie a fundamental difference in the aetiology of 
hypertension in these different ethnic groups, a fact which is perhaps already 
acknowledged by treatment guidelines that reflect a reduced responsiveness 
to inhibition of the renin-angiotensin system in black African and Caribbean 
patients94.   In summary, the role of ADMA in hypertension is likely to involve 
several factors, including the direct effect of NOS inhibition, and the effect 
on renal haemodynamics.  Moreover, increased shear stress is known to 
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increase PRMT activity, and this represents another possible mechanism for 
increased ADMA concentrations6. 
 
Several studies have demonstrated reductions in plasma ADMA concentration 
with short-term angiotensin converting enzyme (ACE) inhibitor treatment; in 
these studies ADMA was reduced by 12 – 20%, and incorporated patients with 
essential hypertension95-97, insulin resistance98, diabetes99 and chronic kidney 
disease (CKD)100.  Angiotensin-receptor blocking drugs produce similar effects 
on ADMA95,97,101, and this may be related in part to inhibition of the effects of 
oxidative stress, such as lipid peroxidation, and so restoration of DDAH 
activity102.  This may be a factor in explaining the protective effects of ACE 
inhibitors on the vascular endothelium, which seem to extend beyond their 
obvious effects on the renin-angiotensin system103. 
 
1.3.3.4  Chronic kidney disease 
CKD is regarded as a risk factor for cardiovascular disease and mortality, with 
the excess in mortality not being explained by traditional vascular risk factors 
alone104.  Patients with end-stage renal failure (ESRF) were first shown to 
have a significant increase in plasma ADMA in the landmark study of Vallance2.  
Since then this observation has been repeated in several studies incorporating 
patients with various stages of CKD and ESRF (reviewed by Jacobi105).  In CKD, 
plasma ADMA concentration is increased, on average, around 2-fold over 
healthy controls, with a wide range of concentrations reported (0.46 – 4.20 
µmol/L)105.  Although plasma ADMA and creatinine concentrations do not 
correlate well as such, ADMA does increase steadily across the stages of 
CKD106,107.  Interestingly, ADMA concentrations are also increased in patients 
with kidney disease but normal renal function as defined by glomerular 
filtration rate (GFR), in whom there is also evidence of increased oxidative 
stress106,108,109.  This, plus evidence from prospective studies, suggests that 
ADMA is involved in the progression of renal disease:  ADMA independently 
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predicts progression to ESRF in patients with CKD, diabetic nephropathy and 
in transplant recipients110-113.  In one study progression to end point (doubling 
of serum creatinine or initiation of renal replacement therapy) occurred 
around 20 months earlier for those with an ADMA concentration above the 
median110.  In another a 0.1 µmol/L increase in ADMA was associated with an 
odds ratio of 1.47 (1.12 – 1.93) for progression111.  The role of ADMA in renal 
disease progression may relate in part to peritubular ischaemia, and in an 
animal model increased expression of DDAH via an adenoviral vector was 
associated with retardation of kidney damage, in particular tubulointerstitial 
fibrosis114.  However, this situation is not clear-cut, given a study of DDAH-1 
polymorphisms which showed that increased DDAH-1 mRNA polymorphism was 
actually associated with a steeper decline in GFR115. 
 
ADMA may also be a determinant of cardiovascular disease in CKD, being 
associated independently with carotid IMT and its progression in patients with 
mild to moderate disease116 and in those with ESRF117.  It is also associated 
with left ventricular hypertrophy and cardiac dysfunction118, and is an 
independent predictor of death in CKD110,119.  As little as a 0.1 µmol/L 
increase is associated with a 20% increase in mortality110, and in haemo-
dialysis patients ADMA is the second strongest predictor of death after age, 
with a  2 – 3 fold increased risk of death for an ADMA concentration above the 
75th centile119. 
 
Haemodialysis reduces ADMA concentration and increases vasodilatation, 
although its clearance is somewhat lower when compared with other low 
molecular weight compounds such as urea and creatinine: the magnitude of 
reduction in plasma ADMA concentration is variable, with reductions of 0 – 80% 
reported105.  It is possible that plasma concentrations are not always a 
reliable guide to the more physiologically relevant intracellular concentration.  
Patients prone to dialysis-associated hypotension have a greater initial 
reduction in ADMA than normotensive equivalents, and a consequent excess of 
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NO may be implicated in the blood pressure lability120.  Following renal 
transplantation, plasma ADMA concentration decreases and is associated with 
improved endothelial function121. 
 
SDMA correlates highly with GFR as determined by inulin clearance (R = 0.85), 
and appears to be a more sensitive marker of renal function than serum 
creatinine122.  Although it could be regarded as the less important 
dimethylarginine, perhaps as a sensitive and non-invasive marker of GFR it has 
a future role.   However, its potential role in reducing arginine availability has 
already been mentioned, and in this context it is interesting to note that its 
concentration is correlated with the angiographic stenosis score in patients 
with mild CKD53.  Moreover, SDMA has been shown to independently predict 
cardiovascular and all-cause mortality in patients referred for coronary 
angiography123. 
 
1.4  ADMA in atherosclerotic disease  
 
1.4.1  ADMA in atherosclerotic disease and prediction of events and mortality 
 
Plasma ADMA concentration is associated with the presence and extent of 
atherosclerotic vascular disease.  In a large multi-centre case-controlled study  
ADMA had the best discriminative power to distinguish cases of coronary heart 
disease (CHD) from controls, with an odds ratio (95% CI) of 6.04 (2.56 – 14.25) 
for those in the highest tertile of ADMA concentration versus the lowest (> 
0.72 and < 0.58 µmol/L respectively)124.  Moreover, in men with early stage 
atherosclerosis ADMA concentration is independently associated with 
measurable endothelial dysfunction, and in this context is also associated with 
the presence of erectile dysfunction, a condition directly attributable to 
reduced NO availability125.  In patients with established CHD, ADMA is 
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associated with the severity of lesions at angiography126.  Patients presenting 
with acute coronary syndromes (ACS) have higher ADMA concentrations than 
those with stable angina127, and these decrease rapidly with medical 
treatment128.  The failure of ADMA concentration to reduce to levels seen in 
stable angina 6 weeks following percutaneous intervention strongly predicted 
recurrence of a cardiovascular event during the following year129.   It is also 
interesting to note that gradients of ADMA concentration have been 
demonstrated in coronary vessels, with higher concentrations distal to 
atherosclerotic plaques than proximal to them (2.39 versus 1.52 µmol/L), 
perhaps reflecting the “local” effects of endothelial dysfunction130.         
 
It is the evidence from longitudinal and prospective studies which provide 
arguably the most compelling case for the role of ADMA as not only a marker, 
but mediator, of atherosclerotic disease, repeatedly showing its predictive 
value independently of traditional and novel risk factors.  This extends to the 
prediction of cardiovascular events, cardiovascular mortality and all-cause 
mortality, in individuals with established atherosclerotic disease, in high risk 
groups and in the general population.  Table  1.1 summarises the major 
findings of these studies, with hazard ratios adjusted for traditional risk 
factors.  Predictive value has been demonstrated in diverse cohorts, including 
ostensibly healthy individuals in the general population131-134, high risk groups 
such as diabetics112,135,136 and those with CKD100,137, in patients with 
established CHD59,138 and following acute coronary syndromes139,140, chronic 
heart failure141, peripheral vascular disease142,143 and primary pulmonary 
hypertension144.  Generally in high risk patients and in those with a prior 
history of CHD, it seems that highest tertile ADMA concentrations are 
independently associated with an apparent doubling of the (relative) risk of 
cardiovascular events and mortality.  This often involves ADMA concentrations 
which are not markedly increased above what might be regarded as “normal” 
by many published studies which have reported reference values (discussed 
later in section on reference intervals), and this partly reflects analytical 
variation between different assay methodologies.  It perhaps also says 
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something about the utility of reference intervals for describing abnormality, 
which is another issue discussed later.  In this sense a parallel can be drawn 
with serum cholesterol concentration and its relationship with atherosclerosis.  
It must also be acknowledged that these studies are not enough to prove a 
causal relationship between ADMA concentrations and vascular disease, with 
possible confounding factors remaining even after adjustment for known risk 
factors.                                                                                                                          
 
1.4.2  Arginine supplementation and the “arginine paradox” 
 
As arginine is the substrate for NO synthesis, the provision of supplemental 
arginine to overcome the effect of ADMA seems an attractive proposition.  
However, as the inherent plasma concentration is in the region of 60 – 80 
µM145, which is far in excess of the Km of around 3.14 µM of eNOS for 
arginine51, in theory arginine availability should not be a limiting to enzyme 
activity and NO production.  Nevertheless, there have been studies suggesting 
a benefit from arginine supplementation on NO production and endothelial 
function.  Indeed, in Vallance’s landmark study, some of the cardiovascular 
effects of ADMA infusion could be offset by simultaneous arginine infusion2.  
Other studies in animals and humans have shown similar results47,54,146-148, and 
oral arginine supplementation has been associated with increased exercise 
capacity in patients with stable angina149 and peripheral vascular disease150.  
The combination of arginine with statin treatment might enhance the effect 
of statin on endothelial function in patients with higher ADMA concentrations, 
in whom ADMA has been proposed to offset, or block, the endothelial effects 
of statins68,151,152.  A meta-analysis of trials involving arginine supplementation 
suggested a benefit on vascular endothelial function in patients with impaired 
flow-mediated dilatation153.  This apparent benefit of arginine 
supplementation when, in theory, its concentration shouldn’t be rate-limiting, 
has been termed the “arginine paradox”154, and might relate to two main 
factors.  First, the competitive nature of its inhibition of NOS, with increases 
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in the apparent Km of the enzyme that can be partially overcome by arginine 
supplementation.  Second, by competition with arginine for transport via the 
cationic amino acid transporter (CAT), for which ADMA has a strong 
affinity51,52.  The physical association of the transporter and eNOS in the 
caveloae of endothelial cells further underlines its importance in delivering 
the arginine to NOS155.  The ratio of arginine to ADMA has thus become a 
parameter which has been increasingly studied, and lower ratios have been 
associated with severity of heart failure and mortality in patients with 
cardiomyopathy156,157 and have been implicated in the link between obesity 
and late-onset asthma, in which reductions in exhaled nitric oxide 
metabolites may be important pathophysiologically158.  Systemic inflammation 
in a population-based cohort correlated negatively with the arginine:ADMA 
ratio, and may therefore explain the link between inflammation and reduced 
NO availability159.  In patients with inflammatory arthropathies, treatment 
with TNF-α antagonists was associated with increases in the arginine:ADMA 
ratio and vascular function160.  Reference values for the arginine:ADMA ratio 
have been described in the healthy population145.  Plasma arginine is a non-
essential amino acid, being synthesised largely in the kidney, although this 
may be insufficient in states of increased demand, i.e. inflammation and 
catabolic stress161. 
 
However, the proposed benefits of arginine supplementation have not been 
demonstrated consistently.  Studies in post-menopausal women162, CHD163, 
healthy men164 and chronic heart failure165 have returned negative results in 
terms of its relatively short-term effects on vascular function.  Furthermore, 
there is a possibility of harm, with arginine supplementation being associated 
with reduced functional capacity in patients with peripheral vascular 
disease166, and with a possible increase in mortality following MI167.  It has 
been speculated that utilisation of the excess arginine by alternative 
metabolic pathways might be responsible, for example, with production of 




The benefits, if any, of arginine supplementation are therefore unclear, and 
there appears to be insufficient evidence to recommend this as a strategy to 
improve vascular endothelial function.  However, the arginine:ADMA ratio 
might represent a useful parameter as a reflection of eNOS substrate to 
inhibitor ratio over and above ADMA concentration alone. 
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Cohort N Follow-up Outcome ADMA concentration Hazard ratio (95% CI) Ref 
General population 3320 10.9 years All cause mortality Per 0.13 µmol/L increase 1.21 (1.07 – 1.37) 131 
Healthy women 880 24 years MI (fatal & non-fatal) and stroke Per 0.15 µmol/L increase 1.29 (1.09 – 1.53) 132 
Healthy men 256 6.2 years MI and sudden cardiac death Highest tertile, > 0.86 µmol/L 2.40 (1.14 – 5.08) 133 
Non-smoking men 150 5 years Acute coronary events Highest quartile, > 0.62 µmol/L 3.92 (1.25 – 12.3) 134 
Type 1 DM & nephropathy 397 11.3 years Fatal and non-fatal coronary events Above median, > 0.46 µmol/L 2.05 (1.31 – 3.20) 112 
Type 2 DM 125 1.75 years Fatal and non-fatal coronary events Highest tertile, > 0.63 µmol/L 2.37 (1.05 – 5.35) 135 
Type 2 DM, angiography 163 2 years All cause mortality Highest tertile, > 1.05 µmol/L 2.63 (1.13 – 6.11) 136 
Chronic kidney disease 131 2.25 years Progression to ESRD and death Per 0.1 µmol/L increase 1.20 (1.07 – 1.35) 110 
Chronic kidney disease 820 9.5 years Cardiovascular mortality Per 0.25 µmol/L increase 1.25 (1.05 – 1.48) 137 
Coronary heart disease 2528 5.45 years Cardiovascular mortality Highest tertile, > 0.89 µmol/L 1.68 (1.18 – 2.41) 138 
Coronary heart disease 1874 2.6 years Fatal and non-fatal coronary events Highest tertile, > 0.70 µmol/L 2.62 (1.52 – 4.51) 59 
Acute coronary syndromes 
(men) 
193 2 years Death, coronary events and stroke Highest tertile, > 1.05 µmol/L 1.81 (1.01 – 3.25) 139 
Myocardial infarction 249 1 year All cause mortality Highest tertile, > 1.14 µmol/L 4.83 (1.59 – 14.71) 140 
Chronic heart failure 253 0.5 years Coronary events and death Highest tertile, > 0.64 µmol/L 2.00 (1.01 – 3.97) 141 
Peripheral vascular disease 496 1.6 years Fatal and non-fatal coronary events Highest quartile, > 0.64 µmol/L 1.70 (1.02 – 2.88) 142 
Peripheral vascular disease 133 2.9 years Major coronary events Highest quartile, > 0.84 µmol/L 5.10 (2.10 – 12.10) 143 
Hazard ratios are presented following adjustment for demographics and known cardiovascular risk factors 
Table 1.1:  Main findings from longitudinal studies of ADMA concentrations and clinical outcomes  
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1.5  ADMA in critical illness 
 
1.5.1  ADMA in the pathogenesis of multiple organ dysfunction 
 
Even with best care, admission to the intensive care unit (ICU) is associated 
with significant mortality, and sepsis is a leading cause of death169.  Sepsis 
and tissue injury are associated with a cascade of responses termed the 
systemic inflammatory response syndrome (SIRS)170, which is a non-specific 
reaction to infectious and non-infectious processes.  This is mediated by 
immune cells and inflammatory cytokines, and is involved in the response to 
infection and tissue repair.  Septic shock describes the occurrence of 
hypotension and impaired tissue perfusion which is often resistant to 
aggressive fluid resuscitation and vasopressor agents, and seems to result 
from a dysregulation of the inflammatory response with multiple organ 
dysfunction resulting from a mixture of excessive inflammation, clotting 
cascade activation and coagulopathy, and dysfunction of the vascular 
enodothelium171.  Septic shock has been termed “warm shock” because of the 
peripheral vasodilatation which is said to distinguish it from cardiogenic and 
hypovolaemic shock, at least in its earlier stages.  It has been proposed that 
excessive NO production is an important mediator of septic shock, at least 
partly explaining the cardiovascular compromise and unresponsiveness to fluid 
and vasopressors172.  NO production from the inducible isoform iNOS can lead 
to highly significant increases in NO 37,172.  While this has a detrimental effect 
on cardiovascular haemodynamics, it is considered an essential part of the 
host defence to infection, through the cytotoxic properties of the 
peroxynitrite ion172,173.  It has been proposed that activation of DDAH with 
increased ADMA clearance facilitates the increase in NO from iNOS in vascular 




The role of ADMA in critical illness and shock is not clear.  It has been 
proposed that ADMA is involved in the development of multiple organ failure 
through its inhibitory effects on constitutive NO production by eNOS176.  
Through a mixture of increased protein turnover, renal and hepatic 
dysfunction, and the direct effects of oxidative stress, hyperglycaemia and 
cytokines on DDAH activity, a potent combination of factors could conspire to 
increase the burden of ADMA, with effects of eNOS impairing organ blood 
flow, as well as other effects including capillary leakage and thrombocyte 
aggregation176.  Moreover, studies in a rat model suggest that in excessive NO 
generation from iNOS might be directly associated with reduced eNOS activity 
and renal dysfunction177.  Therefore, DDAH and ADMA appear well-placed to 
be an important part of not only the pathogenesis of multiple organ failure, 
but also as potential therapeutic targets in the treatment of these patients 
who have a high mortality. 
 
1.5.2 ADMA and mortality in critically ill patients 
 
Significantly increased ADMA concentrations have been reported in ICU 
patients and have been associated with mortality.  In a cross-sectional study 
in ICU, ADMA was an independent and strong marker of outcome, with a 17-
fold increase in mortality for patients in the highest quartile of ADMA18.  In 
this study markers of hepatic function were strongly associated with ADMA 
concentration, suggesting that the liver is an important organ in ADMA 
handling in this context15,18.  Indeed, in a rat model of endotoxaemia a 
significant increase in the hepatic uptake of ADMA was observed, such that 
the fractional excretion increased to 41% compared with a basal value of 
around 27%174.  In another clinical study, plasma ADMA was associated with 
shock, severity of organ failure and inflammatory markers178.  However, the 
situation might be more complex, as significant decreases in the ADMA:SDMA 
ratio have been demonstrated in septic humans, with significant negative 
correlations between inflammatory cytokines and ADMA concentrations179.  
48 
 
This latter observation has been interpreted as reflecting increased ADMA 
catabolism during inflammation179, which presumably would be largely 
mediated by the liver given what has been previously said about studies in 
rats174; furthermore, in septic humans, acute liver failure is associated with a 
significant increase in plasma ADMA concentration and mortality compared 
with septic patients with intact liver function180.   In acute liver failure 
related to paracetamol toxicity, concentrations of ADMA and inflammatory 
cytokines are also significantly correlated181, and plasma ADMA decreases 
rapidly following liver transplantation17,19,181.   
 
In light of what has been already been said about the arginine:ADMA ratio, 
this parameter has been studied in the context of critical illness, though not 
reported in many studies.  In one ICU study, septic patients had a significantly 
lower arginine:ADMA ratio compared with hospitalised (non-septic) controls, 
and lower still in septic patients with shock182.  Moreover, the ratio correlated 
with the severity of organ failure, and was significantly associated with eNOS 
dependent microvascular reactivity182.  The authors of this study speculate 
that as early sepsis (i.e. without shock) is a hyperdynamic state there is 
increased hepatic and, to a lesser extent, renal excretion, with increased 
ADMA concentration as hepatic function falls in shock.  A similar ICU study 
replicated these findings, with the additional observation that a declining 
arginine:total dimethylarginine (sum of ADMA and SDMA)  ratio is 
independently associated with hospital mortality, with an odds ratio of 1.63 
(1.00 – 2.65) per quartile183.  In addition, arginine:dimethylarginine ratio was 
significantly associated with urine nitrate excretion, a surrogate marker of 
overall NOS activity183.  However, previous trials of arginine supplementation 
have produced mixed results, with evidence of potential harm184, therefore 
while the arginine:ADMA ratio might provide information regarding the 
potential interaction of substrate and inhibitor on NO generation, its increase 
by arginine supplementation appears not to be a “quick fix” to improve 
endothelial function and outcomes in critical illness.  This might be related to 
a diversion of arginine from NOS: human endothelial cells exposed to 
49 
 
lipopolysaccharide (LPS) and TNFα develop increased arginase activity185, and 
in humans exposed to intravenous endotoxin the plasma arginine:ADMA ratio 
decreases significantly within 4 hours of exposure186.  In paediatric patients 
with sepsis ADMA concentrations were found to be lower than in febrile and 
healthy controls, although so too were arginine concentrations, which the 
authors speculate to be related to arginase activity187.  This prompted them 
to dismiss ADMA as a cause of endothelial dysfunction in this patient group, 
which raises important questions of how plasma and intracellular 
concentrations are related, given that it is the latter which would be 
expected to be important.  It could also relate to the point in the disease 
process at which the samples were taken; in adult patients with acute 
bacterial infections the recovery phase is associated with a significant 
increase in plasma ADMA concentration, suggesting an initial decrease during 
the early stages of the inflammatory response188.  It might be that the 
significant increases seen in the ICU studies discussed occur at more advanced 
stages in the disease process, when the inflammatory response and organ 
dysfunction are more established.  Lastly, common polymorphisms in the 
DDAH-2 gene may be associated with phenotypic variability in the 
pathophysiology of sepsis and the propensity to haemodynamic 
disturbance178,189. 
 
In summary, increases in ADMA concentrations have been associated with 
organ dysfunction and mortality in critically ill patients, and have been 
speculated to be causally related through effects on NOS.  However, given the 
potentially harmful effects of excessive NO, the intriguing possibility of a 
regulatory role of ADMA acting as a “brake” on iNOS remains34.  Indeed, 
stimulated macrophages and endothelial cells actively take up 
dimethylarginines190,191.  Moreover, while the liver increases ADMA uptake 
during inflammation there is no definite evidence that this is due to DDAH-
mediated catabolism174.  Therefore it is at least theoretically possible that 
increased ADMA uptake acts to achieve this regulatory role.  The distribution 
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of ADMA between the intra and extracellular compartments is further 
considered in relation to the study described later in chapter 8. 
 
1.5.3 Therapeutic manipulation of DDAH and NOS in critical illness 
 
Intensive insulin therapy to maintain normoglycaemia has been associated 
with improved outcomes in ICU192.  It has been proposed that modulation of 
ADMA concentration could account for this beneficial effect193: intensive 
insulin treatment was associated with ADMA concentrations that were lower 
on day 2 compared with those treated conventionally.  Moreover, at the end 
of the study period intensively treated patients had lower ADMA 
concentrations and there was an association between total insulin dose and 
ADMA concentration on the last day193.  These effects could be explained by 
preservation of DDAH activity, given the effect of hyperglycaemia on DDAH 
activity30,194.  Other explanations potentially include reduced protein 
catabolism and increased cellular uptake of ADMA via CATs195. 
 
The potentially harmful effect of excess NO from iNOS has prompted the 
search for NOS inhibitors to improve cardiovascular stability in sepsis and 
critical illness.  Monomethylarginine (MMA) was first studied in this context, 
but was actually associated with increased mortality196.  Similar results were 
demonstrated in patients with cardiogenic shock following MI197.  It is 
probable that the adverse outcomes in these studies related to the non-
specific nature of the NOS inhibition, with eNOS inhibition in particular 
associated with reduced constitutive NO production and organ perfusion.  
More recently, a pharmacological inhibitor of DDAH-1 has been studied in a 
rat model of LPS-induced endotoxic shock198.  In cultured cells, the inhibitor 
specifically reduced NO production in aorta but not macrophages, thus 
permitting selective inhibition of iNOS-mediated NO production in blood 
vessels but not macrophages (which largely express DDAH-2)198.  In LPS-
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treated rats, those treated with the inhibitor demonstrated attenuation of the 
rate of hypotension.  Similar results were seen in heterozygous knockout 
animals (DDAH1+/-), with only modest effects on plasma ADMA 
concentration198.  Both DDAH-1 and DDAH-2 are present in blood vessels, and 
it is now perhaps becoming clear that DDAH-1 is, in fact, of prime importance 
in blood vessels22,86,199, despite what has previously been said regarding the 
tissue distributions of the different isoforms.  While these animal studies are 
promising, it is clear that further work is required to determine whether this 
is a feasible approach for improving cardiovascular stability in septic humans. 
 
1.6 Measurement of dimethylarginines 
 
1.6.1 General analytical considerations 
 
Measurement of ADMA has been most commonly performed in human plasma 
and serum, although urinary measurement, and, increasingly, intracellular 
measurements are being utilised in studies concerned with the physiology and 
clearance of ADMA.  ADMA quantification is rendered difficult by its relatively 
low, submicromolar, concentration, particularly in the presence of many 
other amino acids that are present in far greater concentrations.  A further 
analytical challenge is in achieving separation, generally by chromatography, 
of the structural isomers ADMA and SDMA.  Methods such as high performance 
liquid chromatography (HPLC) and mass spectrometry coupled to gas or liquid 
chromatography permit the simultaneous measurement of arginine, ADMA, 
SDMA, and MMA, which is a distinct advantage, given what has been said 
previously about the increasing use of the arginine:ADMA ratio as a marker of 
NO substrate availability, and the role of SDMA as a marker of renal function, 
and possibly as a cardiovascular risk marker in its own right.  It is also 
generally possible to measure the non-essential amino acid homoarginine, 
which is structurally very similar to arginine, differing only by the length of its 
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carbon skeleton which is 1 carbon atom longer.  Although its role in human 
metabolism is unclear, homoarginine has been proposed to have a role in the 
availability of NO, and is strongly correlated with flow-mediated dilatation 
during normal pregnancies200, and has been independently associated with 
cardiovascular events and mortality in patients referred for angiography202 
and in those undergoing haemodialysis203.  Moreover, a recent report suggests 
an antagonistic relationship with arginine in connection with blood 
pressure201.  Therefore, measurement of endogenous homoarginine 
concentrations might be of interest. While the concentration of MMA in 
plasma is many times less that of ADMA, its intracellular concentration can be 
significantly higher, and thus its measurement might be of interest and 
relevance in cellular studies51.  In summary, therefore, methods for 
dimethylarginine measurement would ideally permit the reliable simultaneous 
quantification of arginine, ADMA, SDMA, MMA and homoarginine, and be 
suitable for plasma/serum, urine and intracellular matrices. 
 
1.6.2 High performance liquid chromatography (HPLC) 
 
HPLC has been the most frequently used method for ADMA analysis, the 
majority of methods employing reverse-phase chromatography with 
fluorescence detection, and have proved reliable and stable, and capable of 
high precision.  Complete separation of ADMA and SDMA can be achieved 
under isocratic conditions205,206,209,201, though some methods have required 
gradient elution204,207,208,211.  A universal requirement is sample clean-up given 
the large number of amino acids and other interfering substances in plasma.  
Solid phase extraction takes advantage of the basic nature of the amino acids 
of interest, using cationic exchangers to select the basic amino acids for 
analysis.  However, this adds a potentially laborious pre-analytical sample 
preparation step to the process, and could thus be considered something of a 
disadvantage.  Furthermore, typical analysis times are in the region of 20 – 40 
minutes, which could also be considered a disadvantage compared with the 
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relatively shorter analysis times using mass spectrometry.  That said, HPLC 
with a monolithic column that permits higher flow rates can reduce analysis 
times to as little as 10 minutes while retaining excellent separation212.   
Furthermore, use of a programmable auto-injector allows batches of 
extracted samples to be analysed, for example, overnight.  One further 
requirement is derivatisation, as the amino acids themselves are not 
fluorescent.  This has commonly been achieved with ortho-phthaldialdehyde 
(OPA) which produces fluorescent adducts that are reliably separated on 
chromatography205,206,208,210,211.  One disadvantage of OPA adducts is their 
relative instability, necessitating derivatisation just prior to analysis to 
prevent significant reductions in fluorescence during analysis206. 
 
An internal standard needs to be added prior to sample preparation, and is 
used essentially to correct for errors during the various pre-analytical 
processes.  An internal standard must, therefore, behave similarly to the 
analytes of interest and be reliably quantified during analysis.  Homoarginine 
and MMA have been frequently employed as internal standards in HPLC, with 
the apparent general view that as they are present in low concentrations in 
plasma, the use of high enough concentrations should avoid large errors from 
their natural variation in biological samples.  However, given what has been 
said about the emerging biological importance of these compounds, 
alternative internal standards might be desirable.  The ideal internal standard 
would be one not inherent in biological samples; in this regard N-propyl-L-
arginine (NPA) has been used, though its separation from the dimethyl-
arginines may not be easily achieved on all columns45.  Characteristics of the 
main HPLC methods, including imprecision and reference values obtained 






1.6.3 Tandem mass spectrometry 
 
Methods based on tandem mass spectrometry (MS/MS) have become popular 
principally as they allow discrimination of ADMA and SDMA based on 
fragmentation pattern, rather than relying solely on chromatographic 
separation which inevitably prolongs the analysis time.  In this way laborious 
sample preparation steps can often be avoided, save for a simple protein 
precipitation step for plasma and serum samples.  However, the lack of a 
specific daughter ion for ADMA often necessitates the coupling of liquid 
chromatography (LC-MS/MS)213-219, which imposes the need to finds a 
compromise between adequate chromatographic separation and analysis 
times that are not too long45.  Derivatisation is required in gas 
chromatography MS/MS (GC-MS/MS)220,221 in order to produce thermally stable 
and volatile derivatives.  In LC-MS/MS, derivatisation is not absolutely 
required; however, butylation, for example, can lead to characteristic 
products which increase specificity to such an extent that analysis times are 
extremely short, making methods suitable for very high throughput of 
samples215.  Potential drawbacks of MS/MS methods include the requirement 
for expensive equipment and technical expertise to develop and optimise 
methods accordingly.  However, when this is available, the advantages of 
simplified sample preparation and higher throughput makes this an attractive 
analytical method.  Table 1.2 shows characteristics of some of the main 
methods. 
 
1.6.4 Enzyme linked immunosorbent assay (ELISA) 
 
An ELISA based method which can quantify ADMA only was developed, with 
the aim of overcoming the drawbacks of HPLC and MS/MS methods as 
considered above222.  This has now been used in several large studies.  Its 
major advantage lies in the high throughput of samples possible with its 96 
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well plate format.  A second ELISA, based on much the same principles, is said 
to offer greater sensitivity223.  The obvious drawback of ELISA lies in its 
inability to measure, on the same sample, the concentrations of relevant and 
related compounds such as SDMA and arginine.  It also appears to be relatively 
imprecise compared with chromatographic methods.  There have also been 
doubts about its accuracy, as discussed in the following section on method 
comparisons. 
 
1.6.5 Between method comparisons 
 
As can be seen from the reference values in table 1.2, results from different 
methods display considerable variability, with mean reference values in so-
called healthy individuals ranging from around 0.37 to 0.78 µmol/L.  It is 
obvious that this magnitude of variation between analytical methods is a 
problem when, as previously discussed, small changes in ADMA concentration 
are associated with significant biological effects.  Indeed, it has been cited as 
a direct hindrance to the assimilation of the large volume of clinical work thus 
far done on ADMA and a barrier to appreciating the level of risk associated 
with ADMA224.   Specifically in renal disease, a review by Jacobi105 nicely 
summarises the position by assimilating the range of “control” values for 
ADMA in renal studies which are meant to represent healthy individuals, 
finding a range of 0.36 – 1.40 µmol/L.  While studies in renal disease have 
been promising, Jacobi notes that “the variability of ADMA levels currently 
precludes useful application of this putative biomarker”105.  The main factors 
behind this variability are likely to include lack of a reference standard and a 
lack of specificity in some chromatography methods45.  Compounding this is 
the relative lack of any comparative studies, and no agreement on what 
constitutes acceptable performance for analytical methods.  In addition to 
between-method variation there is the effect of imprecision, which, as 
Teerlink225 points out, is to reduce statistical power in clinical trials and 
under-estimate the strength of associations in epidemiological studies.  
56 
 
Indeed, an experiment simulating the effect of increasing imprecision in the 
results from a real study shows a rapid falling off of the chance of achieving 
statistical significance, even in the range of 5 – 10%, a level of imprecision 
which some might view as being acceptable225.  It is clear that many of the 
methods summarised in table 1.2 display relatively high imprecision. 
 
There have been a small number of comparative studies evaluating ELISA with 
MS/MS, which seem to highlight a specific problem concerning the calibration 
of the ELISA method.  ELISA appears to over-estimate ADMA concentrations up 
to a factor of 1.5 to 2 in comparison with robust HPLC and LC-MS/MS methods 
despite good correlation226-228.  This suggests a problem with calibration, 
possibly related to matrix-dependent effects, given the calibrators are in an 
aqueous solution.  However, no correlation was noted between the methods 
in another study229.  The increasing number of published studies using ELISA 
highlights the issues of imprecision and bias, and the future of ADMA-based 
research is arguably dependent on standardisation of analytical methods to 
allow assimilation of the burgeoning body of research. 
 
1.6.6 Analytical performance goals 
 
European consensus is that goals, or minimal standards, for the satisfactory 
performance of analytical methods are best defined on the basis of biological 
variation230,231.  Biological variation describes the degree of inherent variation 
both within an individual over time, and between individuals in a population.  
Desirable imprecision is generally set as less than 0.5 times the intra-
individual variation, because at this level analytical variation should have a 
minimal impact on the total test variation230,232.  However, there are virtually 
no data regarding the biological variation of ADMA.  Teerlink225 has estimated 
a narrow between-subject variation, something which is also suggested by the 







Mean ± SD, µmol/L 
Ref 
Gradient RP HPLC, AccQFluor 2.7 0.45 ± 0.07 (n = 30) 204 
Isocratic RP HPLC, OPA 2.5 0.58 – 0.64* (n = 292) 205 
Isocratic RP HPLC, OPA 2.0 0.47 ± 0.08 (n = 53) 206 
Gradient RP HPLC, AccQFluor 6.0 0.44 ± 0.08 (n = 12) 207 
Gradient RP HPLC, OPA < 10.0 0.76 ± 0.12 (n = 35) 208 
Isocratic RP HPLC, NDA 2.3 Range 0.38 – 1.30 (n = 50) 209 
Isocratic RP HPLC, OPA Not stated 0.30 ± 0.05 (n = 7) 210 
Gradient RP HPLC, OPA 5.6 0.58 ± 0.02 (n = 10) 211 
LC-MS/MS, underivatised 4.2 – 5.5 0.46 ± 0.07 (n = 103) 213 
LC-MS/MS, underivatised < 10.0 0.46 ± 0.07 (n = 29) 214 
LC-MS/MS, butyl ester 4.4 0.46 ± 0.09 (n = 85) 215 
LC-MS/MS, underivatised Not stated 0.66 ± 0.12 (n = 15) 216 
LC-MS/MS, underivatised < 8.0 0.37 ± 0.06 (n = 14) 217 
LC-MS/MS, underivatised 6.0% 95% CI 0.44 – 0.46 (n = 42) 218 
LC-MS, OPA 5.7% 0.45 ± 0.13 (n = 15) 219 
GC-MS, methyl PFP 1.6% 0.60 ± 0.08 (n = 10) 220 
GC-MS/MS, methyl PFP 5.8% 0.39 ± 0.06 (n = 12) 221 
ELISA 10.3% 0.65 ± 0.13 (n = 10) 222 
ELISA 4.2% 0.78 ± 0.09 (n = 8) 223 
* Reference values presented as means in four groups stratified according to 
age.  
†  As described in the method validation. 
 
Table 1.2:  Summary of major analytical methods for ADMA measurement 
and associated reference values 
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1.7 Population reference intervals for ADMA 
 
There have been relatively few population studies encompassing a reasonable 
number of well-defined “healthy” individuals.  Teerlink233, using a well 
validated HPLC method, reported a 95% reference interval of 0.39 – 0.63 
µmol/L in a large population based cohort (n = 2,311, mean 0.50 µmol/L, age 
range 50 – 74).  The somewhat older average age of Teerlink’s cohort should 
be acknowledged, as well as the presence of impaired glucose tolerance or 
diabetes in about a third of a cohort, which might influence the results 
obtained234.   Schulze235 reports a 95% reference interval of 0.36 – 1.17 µmol/L 
using ELISA (n = 500, mean 0.69 µmol/L, age range 19 – 75).   Hov236 reported 
data from Norwegian blood donors, showing a 95% reference interval of 0.40 – 
0.77 µmol/L using HPLC (n = 283, mean 0.59 µmol/L, age range 16 – 69).   
Schwedhelm237 reported reference values in healthy non-smoking individuals 
from the Framingham Offspring Cohort, showing a reference interval between 
the 2.5 and 97.5 centiles of 0.31 – 0.73 µmol/L, using LC-MS/MS (n = 1,126, 
mean 0.52 µmol/L, mean age 56). 
 
The higher mean ADMA in study is of Schulze is consistent with what has 
already been said about the comparison between ELISA and chromatography 
methods.  The relatively wider range most likely represents the higher 
imprecision of the assay.  Each of the four studies in the foregoing paragraph 
report a weak but significant correlation between ADMA concentration and 
age.  Furthermore, post-menopausal women have significantly higher ADMA 
concentrations than younger women and younger men233,235-237.  Indeed 
hormone replacement therapy is associated with a decrease in ADMA 
concentrations, which may represent the effect of oestrogen on DDAH238.   
However, these age and gender differences are biologically small, and it has 
been suggested that the generation of age and gender specific reference 
intervals would be of little, if any, benefit235.  Indeed, when this has been 
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done, the mean concentrations between groups are small, with means ranging 
from 0.58 to 0.64 µmol/L in a study by Meinitzer205. 
 
Other studies of greater than 100 individuals have reported results which 
equate to 95% ranges of 0.30 – 0.82 (mean 0.51) µmol/L and 0.32 – 0.62 (mean 
0.50) µmol/L, both using HPLC70,239.  Considering these with results from well 
validated methods (see table 1.2), it seems that an ADMA concentration of 




ADMA is a potent endogenous inhibitor of all NOS isoforms.  ADMA is produced 
ubiquitously following the degradation of protein containing methylated 
arginine residues, and is largely cleared by the enzyme DDAH.  DDAH activity 
is impaired in a number of oxidative stresses, and this, through NOS 
impairment, may be a factor in endothelial dysfunction in patients with 
cardiovascular risk factors.  ADMA has also been associated with the extent of 
cardiovascular disease, and is an independent predictor of cardiovascular 
events and mortality, both in high risk groups and in the general population.  
ADMA may also play a role in the pathogenesis of multiple organ failure in 
critical illness.  Analytical methods for ADMA analysis produce results with 
considerable variability, and this has proven a barrier to the assimilation of 
the large body of clinical work concerning ADMA and perhaps hindered its 
recognition as a potent risk factor and therapeutic target. 
 
Data regarding the biological variation of ADMA are absent from the 
literature, and, consequently, analytical performance goals to guide assay 
development have not been established.  While ADMA has been proposed to 
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play a role in acute inflammation and the regulation of NO, its early response 
during the evolution of the inflammatory response, and how this relates to 
NOS activity, is not known. 
 
1.9 Aims of thesis 
 
1.  To establish an analytical method for the reliable and simultaneous 
measurement of arginine, homoarginine, ADMA and SDMA in biological 
fluids, based on HPLC and simplified to allow its easy adoption in the 
clinical laboratory. 
 
2.  To establish a laboratory reference interval for plasma 
dimethylarginines using the developed method. 
 
3. To establish the intra and inter-individual biological variation of 
dimethylarginines, and from this assess the utility of traditionally 
defined population reference intervals in detecting “abnormality”. 
 
4. Using biological variation data, to establish analytical performance 
goals (imprecision, total error, bias) for analytical methods. 
 
5. To develop a method for measuring urine dimethylamine, the excreted 
product of DDAH-mediated ADMA catabolism, as a marker of whole 
body DDAH activity. 
 
6. To develop a method for measuring urine nitrate excretion, as a marker 




7. To design a study using a suitable patient cohort that will allow 
assessment of plasma dimethylarginine concentrations in the non-
inflamed state, and during the evolution of the acute inflammatory 
response. 
 
8. Using the developed methods, to assess whether significant changes in 
whole body DDAH and NOS activities occur during the inflammatory 




HPLC analysis of dimethylarginines in biological samples 
 
2.1  Principle of method 
 
HPLC involves separation of compounds based on their relative affinities for 
two different phases, a solid, or stationary, phase and liquid, or mobile, 
phase.  Reverse-phase HPLC is most commonly deployed, and describes the 
specific combination of a hydrophobic stationary phase and polar mobile 
phase.  In this type of chromatography analytical columns are often composed 
of silica bonded alkyl chains, C18 being the most popular.  Separation of a 
mixture of analytes is therefore based on their relative hydrophobicity, with 
more hydrophobic compounds tending to adsorb more to the column, delaying 
their progress relative to more polar compounds which have greater affinity 
for the mobile phase.  The composition of the mobile phase, with respect to 
factors such as pH, ionic strength of the buffer, and concentration of organic 
solvent can be manipulated to optimise separation of analytes and the overall 
analytical run time.  Isocratic elution refers to HPLC in which the composition 
of the mobile phase remains constant.  Gradient elution is required when 
some compounds in the mixture are strongly retained on the column, and an 
increase in the organic solvent component of the mobile phase is needed to 
encourage elution; this prevents overly long run times and improves the 
quality and resolution of the peaks obtained.   
 
Once separated on the analytical column, quantitation is based on a detection 
method in which the output of a detector is proportional to the analyte 
concentration.  Commonly used methods include electrochemical, absorbance 
of light, fluorescence and mass spectrometry.  In amino acid analysis, 
fluorescence detection following derivatisation is often employed.  This has 
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the advantage of high sensitivity and specificity, the latter from the specific 
excitation wavelength and wavelength for the re-emission of light.  The 
signals from the detector are captured by data management software, 
resulting in a chromatogram featuring a series of peaks from which analytes 
are quantitated based on relative peak heights or peak areas.  The major 








Figure 2.1:  Schematic diagram of the HPLC system ( from www.lab-
training.com ) 
 
2.2  Specimen collection and pre-analytical handling 
 
2.2.1  Plasma 
 
Plasma was selected as the preferred specimen type.  This was as previous 
studies have shown measured arginine concentrations to be significantly 
higher in serum samples compared with plasma205,225, and that this is 
artefactual owing to release from blood cells.  The choice of anticoagulant, 
i.e. heparin or EDTA, was considered unimportant as they appear to exert no 
influence over measured dimethylarginine concentrations205,225.    
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The time to separation of plasma from the cellular components of blood has 
been previously shown to be non-critical for ADMA and SDMA analysis, with no 
significant change in whole blood after 2 days storage at room temperature205.  
However, arginine does decrease significantly in whole blood, with a 
reduction in the region of 25% after 2 hours240; however, at 30 – 60 minutes 
the change is minimal.  This is most likely due to the effect of arginase from 
lysed erythrocytes or leucocytes, an effect that can be inhibited by storing 
the blood on ice240.  In the studies described in this thesis blood specimens 
were centrifuged promptly after collection, i.e. generally within 30 minutes, 
and definitely within 60 minutes.  However, if longer processing times were 
anticipated it would be advisable to store samples on ice to prevent 
reductions in arginine concentration related to ex vivo metabolism. 
 
Specimens were centrifuged (500 g, 4°C, 10 minutes) and the plasma removed 
into plastic containers.  These were stored at -70°C until analysis. 
 
2.2.2  Urine 
 
Urine was collected into plain specimen containers and stored at -80°C until 
analysis.  After thawing, centrifugation was used to remove any insoluble 
precipitation. 
 
2.2.3  Erythrocyte lysates 
 
After removal of the plasma and buffy coat, packed red cells were stored at -
70°C until analysis.  Three freeze/thaw cycles were deployed to ensure lysis 
of the erythrocyte membranes.  100 µL of packed cells were thoroughly mixed 
with 400 µL of deionised water, and the mixture centrifuged (Eppendorf 
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microcentrifuge Model 5417C) to remove cellular debris.  200 µL of the 
supernatant was used for analysis. 
 
2.3  Reagents and buffers 
 
2.3.1  List of chemicals 
 
Asymmetric dimethyl-L-arginine (Calbiochem, Nottingham, UK) 
Symmetric dimethyl-L-arginine (Calbiochem, Nottingham, UK) 
L-Homoarginine (Sigma chemical company, Poole, UK) 
L-Arginine (Sigma chemical company, Poole, UK) 
Monomethyl-L-arginine (Sigma chemical company, Poole, UK) 
Monoethyl-L-arginine (Calbiochem, Nottingham, UK) 
Boric acid (BDH chemicals, VWR international Ltd, Leicestershire) 
Ortho-phthaldialdehyde (Sigma chemical company, Poole, UK) 
3-mercaptopropionic acid (Sigma chemical company, Poole, UK) 
Sodium acetate (BDH chemicals, VWR international Ltd, Leicestershire) 
Acetonitrile, HPLC grade (Rathburn chemicals Ltd, Walkerburn, Scotland) 
Methanol, HPLC grade (Rathburn chemicals Ltd, Walkerburn, Scotland) 





2.3.2  Preparation of buffers and reagents 
 
2.3.2.1  50 mM borate buffer 
3.1 g of boric acid were dissolved in 1 litre of deionised water, and the pH 
adjusted to 8.5 using 2 M potassium hydroxide.  This was prepared every 4 
weeks to prevent interferences from contaminating substances which was 
seen to occasionally affect older solutions. 
 
2.3.2.2  200 mM borate buffer 
2.5 g of boric acid were dissolved in 200 ml of deionised water, and the pH 
adjusted to 8.5 using 2 M potassium hydroxide. 
 
2.3.2.3  Ammonia/methanol for elution from SPE cartridges 
A  solution containing 10% v/v concentrated ammonia and 50% v/v methanol 
in deionised water. 
 
2.3.2.4  Derivatising agent 
10 mg OPA were dissolved in 200 µL of methanol, then mixed with 1.8 mL of 
200 mM borate buffer.  Finally 10 µL of mercaptopropionic acid were added.  
This stock solution was diluted 1:5 with 200 mM borate buffer prior to use.  
The stock solution stable for approximately 1 week, before a decrease in 
fluorescence occurred owing to instability of the thiol group. 
 
 
2.3.2.5  Mobile phase: 50 mM acetate buffer with 9% v/v acetonitrile 
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A 50 mM sodium acetate buffer was prepared by dissolving 3.73 g of sodium 
acetate in 910 mls of deionised water, and the pH adjusted to 6.3 using 
glacial acetic acid.  90 mls of acetonitrile were added.  The mobile phase was 
filtered through a 0.45 µm nylon filter and degassed prior to use. 
 
2.4  Standards 
 
2.4.1  Preparation of stock standards 
 
As no commercially available standards are available, individual stock 
standards were prepared from pure compounds.  These were made in 10mM 
hydrochloric acid (HCl) at concentrations of 1mM and were stored at -70°C 
until use. 
 
2.4.2  Working standards 
 
A combined calibration standard was made by preparing in deionised water a 
solution containing the four main analytes of interest at the following 
concentrations (table 2.1).  These were aliquoted and stored at -70°C until 
use.  Their stability, as assessed by chromatographic peak heights, was 
determined to be at least 1 year.  When a fresh batch was prepared, 
comparison against the previous lot was used to assign calibrator values and 
ensure continuity in calibration.  As discussed in the section on linearity, a 
single point calibration was chosen, given the linearity of the detector 










Table 2.1:  Analyte concentrations in combined calibration standard   
 
2.5  Internal standard 
 
2.5.1  General requirements of an internal standard 
 
The requirement for a sample cleanup technique involving multiple manual 
steps is a source of random error and thus imprecision.  An internal standard 
is thus added to each standard, QC and sample at the start of the analytical 
process, and so corrects for random errors especially in the sample cleanup 
process.  The ideal internal standard is chemically similar to the analytes of 
interest, thus behaving similarly during extraction and analysis, is well 
resolved from the analytes, and is preferably not inherent in biological 
samples.  MMA and monoethylarginine (MEA) were evaluated, in order to 
compare the performance of the former commonly used internal standard 






2.5.2  Monomethylarginine (MMA) 
 
MMA is the most commonly used internal standard in HPLC methods for ADMA 
analysis, and is chosen because of its relatively low concentration in human 
plasma compared with the other analytes of interest233.  A stock standard of 
MMA was prepared in 10 mM HCl.  This was diluted in deionised water to 
obtain a working solution of 5 µM which was aliquoted and stored at -70°C 
until use. 
 
2.5.3  Monoethylarginine (MEA) 
 
The non-endogenous compound MEA was selected as a candidate internal 
standard.  A stock standard of MEA was prepared in 10 mM HCl.  This was 
diluted in deionised water to obtain a working solution of 5 µM which was 
aliquoted and stored at -70°C until use. 
 
2.6  Internal quality control material 
 
As there are no commercially available QC materials for ADMA, a large plasma 
pool was obtained from the blood transfusion service for use as in-house QC.  
This was stored in aliquots at -70°C until use.  It was analysed in duplicate in 







2.7  Specimen preparation by solid phase extraction 
 
2.7.1  Solid phase extraction (SPE) cartridges and principle 
 
The strongly basic nature of the amino acids of interest make SPE a good 
method for their extraction from the numerous other amino acids in plasma.  
At neutral and weakly basic pH, the amino acids of interest are protonated 
and bind strongly to the cation exchange resin, while other amino acids are 
washed through.  After washing steps, they can be eluted from the column 
using a strongly basic solution.  Isolute PRS columns (1 ml/50 mg cartridges, 
Kinesis Ltd, Epping, UK) were selected as the SPE medium. 
 
2.7.2  Solid phase extraction procedure 
 
200 µL of plasma, standard or QC material were pipetted into small test 
tubes.  To each of these were added 80 µL of the internal standard and finally 
720 µL of 50 mM borate buffer, to create a final volume of 1 mL.  For analysis 
of urine samples, 50 µL of urine were used, with the same quantity of internal 
standard and 870 µL of borate buffer.  This was to bring the higher 
concentrations of ADMA found in urine into a range ensuring linearity of the 
detector response.  Results were multiplied by a factor of 4 to correct for the 
smaller volume of urine used in the analysis. 
 
The SPE cartridges were placed on a Vac Elut extraction system, and 
activated and equilibrated with 2 ml of methanol followed by 2 ml of 50 mM 
borate buffer.  The sample mixtures, as described above, were then run 
through the cartridges.  The columns were then consecutively washed with a 
further 1 ml of borate buffer, 3 ml deionised water and 3 ml methanol.  It was 
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generally possible to perform these steps under gravity, with vacuum suction 
only occasionally required if the flow rate through one or more of the columns 
was sluggish.  Following the washing steps, the amino acids of interest were 
eluted using 3 ml of the 10% ammonia/50% methanol solution and collected 
into glass tubes.  The eluent was then evaporated to dryness at 80°C under 
air.  Using this system, 40 samples could be extracted in approximately 2 
hours. 
 
2.8  Derivatisation 
 
The dried extract was reconstituted in 100 µL deionised water and thoroughly 
mixed.  To that was then added 100 µL of the derivatising agent prepared as 
described above.  After thorough mixing, the tubes were left sitting in the 
dark for 15 minutes in order to ensure completion of the reaction.  The 
derivatised samples were then transferred into auto-sampler vials and placed 
in the autosampler ready for analysis. 
 
2.9  Chromatography 
 
2.9.1  Chromatographic system and setup 
 
The chromatographic system consisted of a solvent delivery system, 
programmable autosampler and fluorimeter (Waters, Watford, UK).  20 µL of 
the derivatised sample was injected by the programmable autosampler onto 
the column for chromatography.  Excitation and emission wavelengths were 
340 nm and 455 nm respectively, the optimal wavelengths for OPA adducts.  
After the elution of arginine the sensitivity was increased, at around 14 
minutes, by adjusting the EUFS (emission units full scale) from 32,000 to 
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8,000.  This was necessary as the concentration of arginine is inherently 
around 100 – 200 times greater than that of the other analytes.  Signals from 
the detector were captured by a data management system (Millennium 2010, 
Waters, Watford, UK).   
 
2.9.2  Analytical column 
 
The analytical column was a Symmetry C18, 4 µm, 4.6 x 150 mm, protected 
by a 3 x 4 mm C18 guard column.  The ambient temperature in the laboratory 
was maintained at a constant level in order to ensure stability of retention 
times. 
 
2.9.3  Mobile phase 
 
The mobile phase, prepared as described, was maintained at room 
temperature and pumped through the analytical column at a flow rate of 1.5 
ml/minute.  The mobile phase was recycled in order to allow a larger number 
of samples to be analysed in a single run without having to prepare overly 
large volumes of the mobile phase.  This was not found to cause any problem 
with interfering peaks, even in continuous runs of up to 100 sample injections. 
 
2.10  Calculation of results 
 
Quantification was done by the method of internal standardisation on the 
basis of peak heights as the analytes were all completely resolved at baseline 
and the peaks consistently sharp and well defined.  Analyte concentrations 
were calculated by dividing the peak height ratio of analyte to internal 
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standard in the (unknown) sample by that in the calibration standard and 
multiplying by the known concentration in the standard.  A single level 
calibration was selected owing to the linearity of all analytes over a wide 
concentration range, as demonstrated in the section on analytical validation. 
 
2.11  Resultant chromatographic profiles 
 
Elution from the analytical column was in the order arginine, MMA, 
homoarginine, ADMA, SDMA and MEA.  All were resolved at baseline and no 
interference from other peaks was a problem.  The retention factors (K’) 
based on the described conditions are given in table 2.2. 
 








Table 2.2:  Retention factors for the analytes of interest 
 
Chromatographic profiles of a combined standard, including MMA, and an 
extracted human plasma sample using MEA as the internal standard are shown 





Figure 2.2:  Chromatographic profiles of (a) a combined standard and (b) 
an extracted human plasma sample.   












2.12  Analytical validation 
 
2.12.1  Linearity 
 
The detector responses were determined to be linear up to 200 µM for 
arginine, 10 µM for homoarginine and 4 µM for ADMA and SDMA under the 
conditions described.  Calibration curves and linear regression equations for 
each of the 4 analytes are shown in figure 2.3.  These were determined by 
preparing sequential dilutions from a stock standard and subjected to the full 
analytical procedure.  The responses on the y axes represent the peak height 
ratios of analyte to internal standard.  The correlation coefficients are > 










Figure 2.3:  Calibration curves and regression equations for arginine, 
homoarginine, ADMA and SDMA 
 
 
2.12.2  Limits of detection and quantification 
 
Limits of detection were defined as 3 times the chromatographic baseline 
noise from a sample blank.  The lower limit of quantification was defined as 
10 times the signal-to-noise ratio.  The results are shown in table 2.3.  The 
lower limit of quantification is significantly lower than the concentrations 






Analyte Limit of detection, µmol/L Limit of quantification, µmol/L 
Arginine 0.01 0.04 
Homoarginine 0.001 0.004 
ADMA 0.001 0.004 
SDMA 0.001 0.004 
 
Table 2.3:  Limits of detection and quantification 
 
2.12.3  Recovery 
 
Accuracy was assessed by determining the recovery of analytes from spiked 
plasma samples.  Increasing concentrations of each analyte were added to 
aliquots of a plasma pool, and the recovery calculated following subtraction 
of the basal concentration.   This experiment was performed in triplicate, and 
the mean (SD) results are shown in table 2.4.  Recoveries were within the 
range 98.0 – 105.4% for arginine, ADMA and SDMA.  For homoarginine, 
recoveries were within the range 92.1 – 93.5% and linear throughout the 













Mean (SD), µmol/L 
Calculated recovery 
Mean (SD), % 
0 79.5 (1.2)  
50 133.9 (0.8) 103.4 (0.6) 
Arginine 
(n = 3) 
100 178.6 (0.3) 99.5 (0.2) 
0 1.57 (0.03)  
2.00 3.46 (0.13) 93.4 (8.3) 
5.00 6.23 (0.08) 92.1 (1.8) 
Homoarginine 
(n = 3) 
10.00 10.97 (0.04) 93.5 (0.5) 
0 0.34 (0.02)  
0.50 0.84 (0.03) 100.0 (6.1) 
1.00 1.35 (0.02) 100.7 (2.6) 
2.00 2.44 (0.01) 105.4 (0.6) 
ADMA 
(n = 3) 
4.00 4.46 (0.07) 103.6 (1.9) 
0 0.27 (0.02)  
0.50 0.77 (0.03) 99.5 (4.2) 
1.00 1.26 (0.05) 99.0 (3.6) 
2.00 2.26 (0.06) 99.6 (2.5) 
SDMA 
(n = 3) 
4.00 4.19 (0.06) 98.0 (1.3) 
 




2.12.4  Precision 
 
2.12.4.1  Intra-assay variation 
The intra-assay CV was determined by analysing 10 aliquots of a single plasma 
pool within a single batch and the results shown in table 2.5.  Each aliquot 
was subjected to solid phase extraction, and so represents the whole 
analytical procedure.    
 Arginine, µmol/L Homoarg, µmol/L ADMA, µmol/L SDMA, µmol/L 
1 57.2 1.79 0.44 0.31 
2 59.6 1.84 0.45 0.32 
3 59.8 1.85 0.45 0.32 
4 59.7 1.80 0.44 0.31 
5 57.2 1.76 0.45 0.31 
6 56.6 1.76 0.43 0.31 
7 58.6 1.78 0.43 0.31 
8 57.4 1.79 0.44 0.32 
9 58.7 1.77 0.44 0.31 
10 56.4 1.76 0.43 0.31 
Mean 58.1 1.79 0.44 0.31 
SD 1.329 0.032 0.008 0.005 
CV, % 2.3 1.8 1.9 1.6 
 
Table 2.5:  Intra-assay variation 
2.12.4.2  Inter-assay variation  
The in-house QC material was analysed in duplicate in each batch.  50 pairs of 
QC duplicates were analysed over approximately 1 year.   Analytical variance 
(SDA
2) was calculated from the difference between each pair of duplicates 
according to the formula: 
SDA
2 = Σ d2/2N 
where d is the difference between each duplicate pair and N is the number of 
duplicates.  Inter-assay CV was calculated from this variance, and is shown in 
table 2.6. 
 
Analyte Mean concentration, µmol/L Inter-assay CV, % 
Arginine 37.3 2.5 
Homoarginine 1.48 2.9 
ADMA 0.36 2.5 
SDMA 0.24 3.2 
 
Table 2.6:  Inter-assay variation 
 
2.12.5 Comparison of internal standards 
 
Comparison of the two potential internal standards was done by analysing 
plasma samples which had both MEA and MMA added as internal standards.  
Arginine, homoarginine, ADMA and SDMA results were then calculated using 
each of the internal standards and the results compared.  Data for a group of 
70 plasma samples is presented in table 2.7.  It can be seen that there are no 
significant differences, and on linear regression, the correlation coefficients 
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are all greater than 0.975.  These results suggest that either internal standard 
can be used without a compromise in accuracy or precision. 
 
Arginine Homoarginine ADMA SDMA 
 
Mean SD Mean SD Mean SD Mean SD 
MEA 60.4 22.3 1.93 0.77 0.46 0.08 0.38 0.08 
MMA 59.6 21.6 1.90 0.74 0.46 0.08 0.38 0.07 
 
Table 2.7:  Comparison of MEA and MMA as internal standards 
 
2.12.6  Stability of analytes in stored plasma samples 
 
Aliquots of the QC material were analysed following 18 months of storage at -
70˚C, with no significant differences seen in the measured concentrations 
from baseline, confirming stability under the described storage conditions.  
The mean (SD) values from 3 measurements 18 months apart are shown in 
table 2.8, with no significant differences seen between the two time points (p 
values all > 0.40). 
 
 Arginine, µmol/L Homoarg, µmol/L ADMA, µmol/L SDMA, µmol/L 
Baseline 34 (1.5) 1.41 (0.01) 0.35 (0.01) 0.24 (0.01) 
18 months 33 (1.2) 1.40 (0.08) 0.36 (0.02) 0.24 (0.02) 
 
Table 2.8:  Stability of analytes in stored plasma samples 
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2.13 Modification of method for measurements in urine 
 
Minor adjustments were made in order to permit measurement of ADMA and 
SDMA in urine, where they are present in much higher concentrations, both in 
the basal state221 and in certain pathological conditions where they can be 
even higher, e.g. liver disease241.  The sample injection volume onto the 
analytical column was reduced to 12 µL, and the detector response was 
assessed to its limit of linearity.  The net result was linearity up to 20 µM for 
both ADMA and SDMA.  Figure 2.4 demonstrates this, with the y axes showing 












Figure 2.4:  Calibration curves and regression equations for ADMA and 




The sample volume taken for solid phase extraction was reduced to 50 µL with 
results increased by a factor of 4, thereby effectively increasing the 
measurable range in urine samples to 80 µmol/L.  This was felt to be 
adequate for the overwhelming majority of human urine samples, based on 
literature values241.  Any samples above this range were analysed following 
dilution. 
 
A recovery experiment was performed identically to that described in plasma 
earlier in the chapter.  Urine was spiked with increasing amounts of ADMA and 
SDMA and the recovery calculated following subtraction of the basal 
concentration.  This was done in triplicate and the mean (SD) results are 
shown in table 2.9.  The recoveries were acceptable, ranging from 95.5 – 






Mean (SD), µmol/L 
Calculated recovery 
Mean (SD), % 
0 9.10 (0.30)  
5 13.88 (0.13) 95.5 (2.5) 
ADMA 
(n = 3) 
10 19.00 (0.01) 99.0 (0.1) 
0 7.44 (0.26)  
5 12.30 (0.24) 97.2 (4.7) 
SDMA 
(n=3) 
10 17.41 (0.06) 99.7 (0.6) 
 




Reference intervals for dimethylarginines 
 
3.1 Materials and methods 
 
3.1.1 Selection of subjects 
 
Ostensibly healthy volunteers from the laboratory staff were selected to 
determine reference intervals for arginine, homoarginine, ADMA and SDMA for 
the current analytical method.  Exclusion criteria were smoking and clinical 
history of a condition known to affect ADMA concentrations, in particular 
cardiovascular and renal disease.  Each individual was informed of the 
purpose and procedure of the study and the exclusion criteria; individuals who 
wished to participate and who didn’t exclude themselves after being informed 
of the exclusion criteria provided consent for blood samples to be taken as 
detailed below.  Increased weight, or body mass index (BMI) was not specified 
as an exclusion criterion, as an independent effect of BMI on ADMA 
concentrations has not been shown.  100 subjects were recruited (51 female, 
49 male), with a mean (range) age of 43 (23 – 65) years. 
 
3.1.2 Specimen collection and handling 
 
Blood was taken by standard venepuncture into tubes containing heparin as an 
anticoagulant, and the plasma removed following centrifugation and stored at 
-70˚C until analysis.  At the same time a sample was taken into a serum 
separator tube (SST) for the analysis of serum lipids (total cholesterol, 
triglyceride, high density lipoprotein (HDL) cholesterol), C reactive protein 
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(CRP), creatinine and alanine aminotransferase (ALT).  This was to exclude 
subjects with significant dyslipidaemias, active inflammation or renal 
impairment, all factors which can affect serum dimethylarginine 
concentrations.  Blood sampling was done under non-fasting conditions, with 
all specimens collected during the early morning after breakfast.  The 
implications of this are discussed in chapter 12.2. 
 
3.1.3 Biochemical analysis 
 
Arginine, homoarginine, ADMA and SDMA concentrations were calculated using 
the method described in chapter 2.  Serum lipids, CRP, creatinine and ALT 
were analysed on a multi-channel autoanalyser in the routine biochemistry 
laboratory, using methods described briefly in chapter 7.  Low density 
lipoprotein (LDL) cholesterol was calculated according to the Friedewald 
equation (total cholesterol – HDL – (triglyceride/2.2)).  Estimated glomerular 
filtration rate (eGFR) was calculated using the standard 4 variable 
modification of diet in renal disease (MDRD) formula, as appropriate to the 
creatinine method in use in NHS Greater Glasgow and Clyde laboratories242: 
eGFR (ml/min/1.73m2) = 175 × (Creatinine/88.6)-1.154  × (Age)-0.203 × 0.742 if 
female 
 
3.1.4 Statistical methods 
 
The data for arginine, homoarginine, ADMA and SDMA were examined for 
normality using the Kolmogorov Smirnov test.  Non-normally distributed data 
were logarithmically transformed.  Means and 95% reference intervals were 
constructed from the transformed data.  Correlations between ADMA and 
other parameters was done using Spearman rank correlation where variables 
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were non-normally distributed.  Differences between age and gender 
stratified groups were examined using the Mann Whitney U test. 
 
3.2  Results 
 
3.2.1  Population distribution  
 
Biochemical data for all of the subjects examined can be seen in appendix 2.  
The means, medians and SDs from the raw data are presented in table 3.1. 
 
Analyte Mean, µmol/L Median, µmol/L SD, µmol/L 
Arginine 68.5 65.7 26.4 
Homoarginine 1.99 1.86 0.84 
ADMA 0.46 0.45 0.084 
SDMA 0.39 0.38 0.077 
 
Table 3.1:  Means, medians and SDs of reference group data (n = 100) 
 
The reference values for all four analytes in table 3.1 were found to be non-
normally distributed.  Therefore logarithmic transformation was employed to 
normalise the distributions.  Probability plots and histograms of the 








Figure 3.1(a) Probability plot and histogram of reference values for 







Figure 3.1(b)  Probability plot and histogram of reference values for 







Figure 3.1(c)  Probability plot and histogram of reference values for ADMA 






Figure 3.1(d)  Probability plot and histogram of reference values for SDMA 




3.2.2 Calculation of reference intervals 
 
95% reference intervals were derived conventionally by defining lower and 
upper limits 2 SDs either side of the logarithmically transformed means.  The 
resultant reference intervals are shown in table 3.2 
 
Analyte Mean, µmol/L 95% reference interval, µmol/L 
Arginine 63 27 – 148 
Homoarginine 1.83 0.82 – 4.09 
ADMA 0.45 0.32 – 0.65 
SDMA 0.38 0.26 – 0.56 
 
Table 3.2:  95% reference intervals following logarithmic transformation 
 
3.2.3 Age and gender influences 
 
3.2.3.1  Comparison of gender stratified groups 
The data for the four analytes in question was divided according to gender, 
and comparisons made between gender groups.  The median arginine 
concentration was higher in men compared with women, but no other gender 
differences were seen.  Table 3.3 shows the median concentrations and p 





 Arginine Homoarginine ADMA SDMA 
Male, µmol/L 75 (53 – 93) 1.86 (1.39 – 2.47) 0.42 (0.38 – 0.52) 0.40 (0.34 – 0.44) 
Female,  µmol/L 62 (48 – 79) 1.87 (1.37 – 2.49) 0.45 (0.41 – 0.52) 0.37 (0.33 – 0.41) 
p value 0.03 0.93 0.26 0.22 
 
Table 3.3:  Median (inter-quartile range) values and p values for 
comparisons of reference group stratified by gender 
 
3.2.3.2 Associations with age 
No significant correlations were seen between ADMA and SMDA concentrations 
and age, both displaying Spearman rank correlations of 0.14 and 0.18 
respectively.  The female group was divided according to age into two groups 
of < 50 years and ≥ 50 years in order to investigate the effect of menopausal 
status.  The age cut off of 50 years was selected as it represents the typical 
age of menopausal transition.  No significant differences were seen between 
the groups (p = 0.35). 
 
3.2.4 Correlations of dimethylarginines with other variables 
 
SDMA and ADMA were strongly correlated (r = 0.53, p < 0.001).  There was a 
borderline weak correlation between SDMA and serum creatinine (r = 0.19, p = 
0.08).  These are shown in figures 3.2 and 3.3 respectively.  The correlation 
between SDMA and creatinine was weaker than reported in other studies, but 
the range of creatinine values encountered was somewhat narrower, which 
probably accounts for the apparently lesser strength of the association.  No 
significant correlation was seen between SDMA and eGFR (r = -0.10, p = 0.36), 
although any potential association between SDMA and renal function could 
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have been undermined by the use of non-fasting samples which can affect 
serum creatinine concentrations243, and the range of encountered eGFRs 
which are overall in the range where the MDRD equation is known to perform 
less well242 (mean eGFR in reference group 78 ml/min/1.73m2). 
 
No correlations were seen between SDMA and other variables.  ADMA 
demonstrated no correlations with total cholesterol (r = -0.11, p = 0.31), LDL 
cholesterol (r = -0.116,   p = 0.28), serum creatinine (r = -0.10, p = 0.334) 











Figure 3.2:  Relationship between ADMA and SDMA concentrations in 
reference group 
 








Biological variation of dimethylarginines 
 
4.1 Biological variation and its utility 
 
4.1.1  Background to biological variation 
 
Any analyte measured repeatedly will demonstrate inherent variation in the 
serial results obtained.  Broadly speaking this variation consists of two main 
sources: that related to random variation in the assay, and that which is 
inherent in the individual and can be considered as random around a 
homeostatic set point.  This is termed the intra-individual biological variation 
(CVI).  Homeostatic set points differ between individuals, and this is termed 
the inter-individual variation (CVG)
244.  A parameter which is homeostatically 
important, such as blood pH or extracellular potassium concentration, would 
be expected to have a rather narrow intra-individual variation owing to the 
action of regulatory mechanisms, while a parameter not subject in itself to 
regulation, such as urine osmolality, would display a much wider 
variation244,245.  Certain analytes have predictable cyclical rhythms which 
might be diurnal, e.g. serum cortisol, monthly, e.g. female reproductive 
hormones or seasonal, e.g. vitamin D.  Additionally some analytes exhibit 
changes according to age, or at certain times of life such as puberty, 
pregnancy or menopause.  As has been discussed in the introduction, ADMA 
has been shown to increase, although by a small absolute amount, with 
increasing age and after the menopause.  However, little is known about its 
biological variation, although such data is required in order to assess its 
biological significance, determine the likely significance of changes in serial 




In order to determine the components of biological variation, repeated 
specimens are taken from a group of individuals under standardised 
conditions.  In general it is advised to select a small number of reference 
subjects who are free from disease or medication known to affect the analyte 
being measured; they should be sampled under standardised conditions, and 
samples analysed within a single analytical batch in order to minimise the 
effect of pre-analytical and analytical variation230,232. 
 
4.1.2  Reference change value 
 
Biological variation data are also used to determine the reference change 
value (RCV).  Laboratory tests are often measured repeatedly, with changes 
between measurements used to monitor such factors as disease progression or 
response to treatment, both in clinical practice and in studies.  Since some 
variation will be expected from biological variation, the RCV is useful in 
describing the magnitude of difference required to be confident of a 
biologically significant change at a certain level of statistical 
significance232,244. 
 
4.1.3  Index of individuality and the utility of reference intervals 
 
Reference intervals are often regarded as being equivalent to “normal 
ranges”, although clearly there will be, sometimes considerable, overlap 
between healthy and diseased individuals.  Many analytes measured in clinical 
laboratories exhibit a CVI which is much less than the CVG, a prime example of 
this being serum creatinine244-246.   In practice this means that the majority of 
individuals have a range of “normal” values which are contained within a 
fraction of the overall reference interval, be this in the middle of the range or 
at either extreme.  An individual could, therefore, have a result which is 
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highly unusual for them but still within the overall reference interval246.   The 
index of individuality (II) is derived from the components of biological 
variation and describes exactly this “biological individuality”, and is used to 
assess the utility of traditionally-defined reference intervals in denoting 
abnormality in a single measurement on a single occasion246.  Essentially it is 
the ratio of CVI to CVG.  A ratio of > 1.4 generally means that a population 
derived reference interval can be used to denote “abnormality” in an 
individual with a reasonable degree of likelihood.  In contrast, a ratio < 0.6 
indicates that an isolated result has limited diagnostic utility when compared 
with a reference interval246. 
 
4.1.4  Analytical performance goals 
 
Performance goals for analytical methods are best based on biological 
variation230,231.  These goals are designed to ensure that, at acceptable levels 
of performance, variation from analytical “noise” does not obscure clinical 
“signal”, and cover both random error, i.e. imprecision, and systematic error, 
i.e. bias.  A desirable goal for imprecision has been set as no more than 0.5 





4.2.1 Specimen collection and handling 
 
Twelve ostensibly healthy individuals, members of the biochemistry 
laboratory staff at Glasgow Royal Infirmary, were recruited (6 men, 6 women, 
age range 20 – 53 years).  None had any disease known to affect ADMA 
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concentrations, and none were on regular medication.  All were non smokers, 
and none consumed alcohol in excess of recommended safe levels.  All 
maintained their usual lifestyles for the duration of the study. 
 
Once per week for 20 weeks blood was collected by conventional 
venepuncture following an overnight fast.  These were collected between 
09:00 and 10:00 in the morning with subjects in a sitting position and avoiding 
venous stasis.  Blood was collected into tubes containing heparin as an 
anticoagulant, centrifuged (500 g, 4˚C, 10 minutes), and the plasma 
transferred into plastic tubes which were stored at -70˚C until analysis. 
 
Plasma arginine, homoarginine, ADMA and SDMA were measured using the 
method described in chapter 2.  As there were 20 samples from each 
individual, they had to undergo solid phase extraction in 2 lots, although all 
were analysed in a single analytical run.  The analyses were performed by a 
single analyst, with a single lot of reagents, QC and calibration standards, in 
order to minimise analytical variation. 
 
4.2.2 Statistical methods 
 
Statistical analysis was carried out using Minitab statistical software (release 
13).  Data were examined for normality using the Anderson Darling test, and 
outliers defined as data points exceeding 3 SD from the mean.   
 
4.2.2.1  Determination of the components of biological variation 
For each analyte, the total intra-individual variance was calculated from the 
data for each participant and transformed into the total intra-individual CV 
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(CVTI) using the homeostatic mean from each participant.  CVTI  consists of 
both biological and analytical components, therefore the intra-individual 
variation was calculated by subtraction using the general formula: 
CVI  =  (CVTI
2  -  CVA
2)1/2 
The intra-assay CV, as described in section 2.12.4.1 was used as the CVA for 
this calculation, given that samples for a single individual were analysed in a 
single batch. 
 
The inter-individual variance reflects the difference between means of 
individuals.  It was determined by use of all the individual data points and 
transformed into the total inter-individual CV (CVT) by use of the overall 
mean.  The CVI and CVA were subtracted from this to give the CVG, according 
to the formula: 
CVG  =  (CVT
2  -  CVI
2  -  CVA
2)1/2 
 
4.2.2.2 Determination of reference change value and index of individuality 
The RCV was calculated with a view toward providing information about 
significant change at the 95% confidence level.  It was thus calculated as 
follows232: 
RCV  =  2.77  x  CVTI 
 
The II is simply the ratio of intra and inter-individual variances, as was 
calculated according to the formula246: 





4.2.2.3 Determination of analytical performance goals 
The desirable goal for imprecision (CVA)
230,231 was calculated as ≤ 0.5 x CVI. 
 
The limiting goal for bias (B) is one fourth of the group biological variation 
which is itself made up of intra and inter-individual components230,231.  The 
goal was defined as: 
B  <  0.25  x  (CVI
2  +  CVG
2)1/2 
 
The resultant goal for total error (TE)230,231 is defined as <  (kI + B), where k = 




4.3.1 Intra- and inter-individual biological variation 
 
The data for arginine, homoarginine, ADMA and SDMA were all found to be 
normally distributed in each individual.  Two outlying data points were 
excluded.  For each individual participant the mean analyte concentrations, 
SD and resultant CVI are shown in appendix 2.  The mean CVI values are shown 
in table 4.1.  As can be seen, ADMA and SMDA exhibit tight regulation in 
human plasma, with values of 7.4% and 5.8% respectively.  Arginine and 
homoarginine are less tightly controlled, though are much less variable than 










Arginine 16.1 13.4 
Homoarginine 14.4 37.8 
ADMA 7.4 9.6 
SDMA 5.8 14.7 
 
Table 4.1:  Biological variation of arginine, homoarginine, ADMA and SDMA 
 
The CVG values are also shown in table 4.1.  For ADMA and SDMA the results of 
9.6% and 14.7% respectively suggest a spread in the population which is not 
excessively high, as has been suggested by the data from the various clinical 
studies examined in chapter 1.  However for SDMA in particular it is striking 
that CVI is much less than CVG (5.8% vs 14.7%), suggesting a high degree of 
biological individuality, analogous to serum creatinine.  This can be 
appreciated visually by examining figure 4.1, which contains box plots 
depicting the range of values encountered in each individual studied.  SDMA, 
ADMA and homoarginine show this individuality visually, with the individual 


































































































Figure 4.1:  Box plots of arginine, homoarginine, ADMA and SDMA 
concentrations in biological variation study 
 
4.3.2 Reference change value and index of individuality 
 
The RCVs and IIs are shown in table 4.2.  The RCVs for ADMA and SDMA are 
around 20%, indicating that a change of at least this magnitude is required 
between serial samples to be confident of biological significance.  The IIs 











Reference change value 
RCV, % 
Index of Individuality 
II 
Arginine 45.7 1.23 
Homoarginine 41.0 0.39 
ADMA 21.6 0.81 
SDMA 19.1 0.47 
 
Table 4.2:  Reference change values and indices of individuality 
 
4.3.3 Analytical performance goals 
 
Performance goals for imprecision, bias and total error are shown in table 4.3.  
The low CVI of ADMA and SDMA imposes fairly tight imprecision goals, which 
numerous methods described in the literature fail to meet.  The right-hand 
column gives the performance of the current analytical method as determined 


















Arginine 8.0 5.2 10.3 2.5 
Homoarginine 7.2 10.1 16.0 2.9 
ADMA 3.7 3.1 7.2 2.5 
SDMA 2.9 3.9 10.0 3.2 
 
Table 4.3:  Analytical performance goals 
 
4.4  Summary and conclusions 
 
The biological variation of ADMA and SDMA in human plasma is low, suggesting 
fairly tight regulation.  This imposes strict analytical performance goals, 
something which many methods fail to meet.  The indices of individuality of < 
1.4 suggest that reference intervals are of limited utility in denoting 
abnormality from a single result.  This is likely to hamper efforts to 




Measurement of dimethylamine in urine using HPLC 
 
5.1 Background and justification 
 
Dimethylamine (DMA) is a short chain aliphatic amine derived from the DDAH-
mediated catabolism of ADMA, and is excreted in the urine247.  It was first 
identified in human urine several decades ago, and has endogenous and 
exogenous sources248.  Theoretically its excretion rate could provide a 
surrogate measure of overall DDAH activity, provided that two conditions are 
met: first, that once produced DMA is excreted entirely, or largely, unchanged 
in urine; and, second, that exogenous, that is dietary, sources of DMA can 
either be minimised or eliminated to prevent excessive background “noise” 
obscuring the variation attributable to changes in endogenous production.  On 
the first of these conditions, an experiment has shown that ingested DMA is 
excreted rapidly into the urine unchanged:  87% of an oral dose of DMA was 
excreted into the urine during the first 24 hours in healthy male volunteers, 
with only a small amount (5%) further metabolised249.  The elimination half-
life from plasma was estimated to be 6 – 7 hours249.  Moreover, as little as 2 
hours following IV injection of ADMA, a significant increase in urinary DMA is 
seen8.  On the second condition, the dietary sources of DMA have been well 
characterised.  In a study of dietary sources, no foods from the fruit and 
vegetable, meat, dairy or grain groups produced any significant increases in 
DMA excretion following ingestion250.  On the contrary, most fish and shellfish 
produced significant increases in its excretion, especially squid, coley, 
whiting, cod and sardines, and appears to be related to the breakdown of 
trimethylamine N oxide within the fish after being caught250.  It appears that 
by restricting access to this specific food group, major fluctuations from diet 




The excretion of DMA in human urine has been estimated at around 140 to 400 
µmol/day8,247,251, with a urinary ratio of DMA to ADMA of around 10.  The 
concentrations of DMA and ADMA in urine are significantly correlated (R = 
0.84), further suggesting the validity of extrapolating DMA to ADMA 
catabolism251, and has a relatively low variation on a stable diet.    In patients 
with coronary disease, urinary excretions of ADMA and DMA are both 
increased, with an increase in the DMA:ADMA ratio, but retention of their 
positive correlation251. In view of these facts urinary DMA excretion was 
measured as an indicator of overall DDAH activity. 
 
Published methods for DMA include GC-MS/MS247,251 and HPLC252 .  The 
described GC-MS/MS requires pre-analytical sample extraction using toluene 
and derivatisation to produce pentafluorobenzamide derivatives251.  Using 
HPLC, DMA was converted to a stable fluorescent derivative using 9-
fluorenylmethylchloroformate  (FMOC) which permits reliable and sensitive 
measurement by fluorescence detection252.  The HPLC method has the 
advantage of simpler sample preparation, but requires a heating step to 
eliminate a prominent interfering peak related to the derivatising agent itself.  
Both methods demonstrate high sensitivity and acceptable precision, with 
inter-assay CVs of around 5% or less251,252.  In the current study, a method was 
developed using HPLC, taking the method of Teerlink252 as a starting point, 
with modifications to allow greater simplicity.  The remainder of this chapter 
describes its development and analytical validation. 
 
5.2  Specimen collection and pre-analytical handling 
 
Urine was collected into plain specimen containers and the samples 
immediately frozen to ensure stability of DMA.  Samples were stored at -70˚C 




5.3  Reagents and buffers 
 
5.3.1  List of chemicals 
 
Dimethylamine (BDH chemicals, VWR International Ltd, Leicestershire) 
Trichloroacetic acid (Sigma chemical company, Poole, UK) 
Boric acid (BDH chemicals, VWR International Ltd, Leicestershire) 
9-fluorenylmethylchloroformate (FMOC) (Sigma chemical company, Poole, UK) 
Glycine (Sigma chemical company, Poole, UK) 
Potassium dihydrogen phosphate (BDH chemicals, VWR International Ltd, 
Leicestershire) 
Methanol, HPLC grade (Rathburn chemicals Ltd, Walkerburn, Scotland) 
Ethanol, HPLC grade (Rathburn chemicals Ltd, Walkerburn, Scotland) 
 
5.3.2  Preparation of buffers and reagents 
 
5.3.2.1  10% trichloroacetic acid (TCA) 
20 g TCA were dissolved in 200 ml deionised water. 
 
5.3.2.2   0.8 M borate buffer 
9.92 g boric acid were dissolved in 200 ml deionised water, and the pH 
adjusted to 9.5 using 2 M potassium hydroxide. 
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5.3.2.3  Derivatising agent 
A 10 mM solution of the derivatising agent was prepared by dissolving 26 mg 
FMOC in 10 mls acetonitrile.  This was prepared freshly prior to each 
analytical run. 
 
5.3.2.4  100 mM glycine 
75 mg glycine were dissolved in 10 ml deionised water. 
 
5.3.2.5  Mobile phase:  50 mM phosphate buffer, 60% v/v methanol,          
10% v/v ethanol 
A 50 mM phosphate buffer was prepared by dissolving 0.5 g potassium 
dihydrogen phosphate in 150 ml deionised water, and the pH adjusted to 6.5 
using 2 M potassium hydroxide.  To this was added 300 ml methanol and 50 ml 
ethanol.  The mobile phase was filtered through a 0.45 µm nylon filter and 
degassed prior to use. 
 
5.4  Standards 
 
A 10 mM stock DMA standard was prepared in deionised water and stored at -
70˚C.  From this a 250 µM working standard was prepared for use in each 
analytical run.  The standard was determined to be stable under these 






5.5  Internal quality control material 
 
Urine obtained from a single volunteer was used as the QC material.  This was 
stored in aliquots at -70˚C until use, and analysed in duplicate within each 
analytical run in order to generate imprecision data. 
 
5.6  Specimen preparation and derivatisation 
 
300 µL of sample, standard or QC were mixed with 200 µL of 10% TCA, the 
acidification stabilising the volatile DMA in solution and allowing precipitation 
of any protein in the samples.  Following centrifugation (1000 rpm, 10 
minutes), 200 µL of the supernatant were mixed thoroughly with 600 µL 0.8 M 
borate buffer.  400 µL of this mixture were then added to 300 µL of the 
derivatising agent, and the reaction allowed to proceed for 1 minute.  The 
excess derivatising agent was then neutralised by the addition of 100 µL 100 
mM glycine.  The resulting solution was transferred into a glass tube with a 
screw fitting cap and placed on a heating block at 80˚C for 10 minutes.  The 
heating step was employed to eliminate a peak which eluted on 
chromatography very close to the DMA peak.  This problem was previously 
described by Teerlink252, who demonstrated complete removal of the 
interfering peak with no effect on the DMA peak.  The same experience was 
obtained in the present study.  Following heating samples were diluted 1:10 in 







5.7  Chromatography 
 
5.7.1  Chromatographic system and setup 
 
The chromatographic system consisted of a solvent delivery system, 
programmable autosampler and fluorimeter (Waters, Watford, UK).  10 µL of 
the derivatised sample was injected by the programmable autosampler onto 
the column for chromatography.  Excitation and emission wavelengths were 
260 nm and 320 nm respectively, the optimal wavelengths for FMOC 
derivatives.  At 10 minutes the sensitivity was increased by adjusting the EUFS 
(emission units full scale) from 32,000 to 4,000.  The low detector sensitivity 
at the start of the analytical run was selected as two large peaks elute near 
the start, namely the hydrolysis product of the derivatising agent, FMOC-OH 
and the FMOC-glycine derivative252.   Following their elution, the detector 
sensitivity was increased to allow reliable quantification of DMA within the 
linear part of the detector response.  Signals from the detector were captured 
by a data management system (Millennium 2010, Waters, Watford, UK).   
 
5.7.2  Analytical column 
 
The analytical column was a Luna C18, 5 µm, 4.6 x 250 mm, protected by a 3 
x 4 mm C18 guard column.  The ambient temperature in the laboratory was 







5.7.3  Mobile phase 
 
The mobile phase, prepared as described, was maintained at room 
temperature and pumped through the analytical column at a flow rate of 1.0 
ml/minute.  The mobile phase was recycled in order to allow a larger number 
of samples to be analysed in a single run without having to prepare overly 
large volumes of the mobile phase.  This was not found to cause any problem 
with interfering peaks, even in large runs. 
 
5.8 Calculation of results 
 
Quantification was done by the method of external standardisation on the 
basis of peak heights as the DMA peak was completely resolved at baseline 
and the peak consistently sharp and well defined.  DMA concentration was 
calculated by dividing the peak height of analyte in the (unknown) sample by 
that in the calibration standard and multiplying by the known concentration in 
the standard.  A single level calibration was selected owing to the linearity of 
DMA over a wide concentration range, as demonstrated in the section on 
analytical validation. 
 
5.9  Resultant chromatographic profiles 
 
The peak corresponding to DMA was completely resolved from all other peaks.  
Chromatographic profiles corresponding to an aqueous standard and human 







Figure 5.1:  Chromatographic profiles of (a) an aqueous standard and (b) a 
human urine sample.   The DMA peak is seen to elute at 12.4 minutes. 
 
5.10  Analytical validation 
 
5.10.1  Linearity 
 
The detector response was determined to be linear up to 2,000 µM for DMA 
under the conditions described.  Calibration curve and linear regression 
equation for DMA are shown in figure 5.2.  These were determined by 
preparing sequential dilutions from a stock standard and subjected to the full 
analytical procedure.  The values on the y axes represent the detector 






Figure 5.2:  Calibration curve and regression equation for dimethylamine 
 
5.10.2  Limits of detection and quantification 
 
Limit of detection were defined as 3 times the chromatographic baseline 
noise from a sample blank, and was determined to be 2 µmol/L.  The lower 
limit of quantification was defined as 10 times the signal-to-noise ratio, and 
was determined to be 6.7 µmol/L.  The lower limit of quantification is 








5.10.3  Recovery 
 
Accuracy was assessed by determining the recovery of DMA from spiked urine 
samples.  Increasing concentrations of DMA were added to aliquots of a urine 
pool, and the recovery calculated following subtraction of the basal 
concentration.   This experiment was performed in triplicate, and the mean 






Mean (SD), µmol/L 
Calculated recovery 
Mean (SD), % 
0 351 (12.7)  
250 597 (9.6) 98.4 (3.2) 
500 859 (13.3) 101.5 (2.2) 
1000 1350 (20.9) 99.9 (1.7) 
 
Table 5.1:  Recovery of dimethylamine from spiked urine samples (n = 3) 
 
5.10.4  Precision 
 
5.10.4.1  Intra-assay variation 
The intra-assay CV was determined by analysing 5 aliquots of a single urine 
pool within a single batch.  Each aliquot was subjected to the described 
process, and so the data represent the imprecision of the whole analytical 
procedure.  The results from this are shown in table 5.2. 
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CV, % 2.8 
   
Table 5.2:  Intra-assay variation 
 
5.10.4.2  Inter-assay variation 
The in-house QC material was analysed in duplicate in each batch.  12 pairs of 
QC duplicates were used to determine imprecision.  The data for these are 
given in table 5.3.  Analytical variance (SDA
2) was calculated from the 
difference between each pair of duplicates according to the formula: 
SDA
2 = Σ d2/2N 
where d is the difference between each duplicate pair and N is the number of 
duplicate pairs.  Inter-assay CV was calculated from this variance, and was 





Pair no Sample 1, µmol/L Sample 2, µmol/L 
1 407 401 
2 363 372 
3 333 344 
4 430 416 
5 367 380 
6 366 381 
7 348 382 
8 376 349 
9 340 358 
10 366 392 
11 377 353 
12 379 362 
 




Measurement of nitrate in urine using HPLC 
 
6.1  Background and justification 
 
NO has a very short half life in the circulation, rapidly reacting with 
oxyhaemoglobin (oxyHb) to form nitrate which is its major, inactive, 
metabolite253.  A small amount undergoes oxidation to nitrite, which can also 
be oxidised by oxyHb.  While NO itself is unstable, nitrate as the major 
metabolite of NO undergoing urinary excretion provides a relatively simple 
and non-invasive marker of whole body NO production.  The most commonly 
used methods for measurement of nitrate in biological fluids are based on the 
Griess reaction, and involve a modification of the original method in which 
nitrite reacts with the amino group of sulphanilamide under acidic conditions 
to form a diazonium cation254.  This couples typically with 
naphthylethylenediamine to form an azo dye which can be measured by 
absorption of light at 540 nm.  For urinary nitrate measurement, the nitrate 
must first be reduced to nitrite using nitrate reductase.  Therefore total nitric 
oxide metabolites (sum of nitrate and nitrite) are measured, with the 
overwhelming majority representing nitrate.  A significant problem with these 
methods is the incomplete reduction of nitrate, which has been estimated at 
around 30 – 80%255.  GC-MS and HPLC methods have also been utilised, but 
suffer in comparison with the Griess methods owing to the equipment 
required, and sometimes extensive pre-analytical sample preparation to avoid 
interferences254. 
 
Nitrate excretion in urine is also contributed to by dietary nitrate, although 
compared with dietary sources, endogenously formed nitrate has been 
estimated as being 3 to 6 times greater254,256.  Dietary sources of nitrate 
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include green vegetables, processed meats and tap water.  Following a high 
nitrate meal, urinary nitrate peaks after 4 – 6 hours, with the majority 
excreted during the following 12 hours and a return to near basal levels by 16 
hours257.  When collecting serial samples to examine for changes in 
endogenous nitrate production, therefore, it is important to standardise the 
collection time and minimise the variation from changes in the “background” 
excretion from dietary sources. 
 
The remainder of this chapter describes the development and validation of a 
simplified isocratic HPLC method for measurement of nitrate in urine and its 
comparison with a commonly used commercially available Griess colorimetric 
assay. 
 
6.2  Specimen collection and pre-analytical handling 
 
For patients participating in the knee arthroplasty study described in chapter 
8, urine samples were collected in the morning before or around the time of 
breakfast.  The patients’ evening meal was at a consistent time around 17:30 
to 18:00 hours and was their last main food intake of the day. Urine samples 
being collected in the morning around 14 hours after this on average.  
Random samples were collected and the nitrate concentrations expressed as a 
ratio to creatinine.  Urine specimens were collected into plain specimen 
containers.  These were frozen without significant delay, and stored at -70˚C, 
being thawed only immediately prior to analysis.  This was done to prevent 






6.3  Reagents and buffers 
 
6.3.1  List of chemicals 
 
Sodium nitrate (Sigma-Aldrich, Gillingham, UK) 
Potassium dihydrogen phosphate (BDH chemicals, VWR International Ltd, 
Leicestershire) 
 
6.3.2  Preparation of mobile phase: 20 mM phosphate buffer 
 
A 20 mM phosphate buffer was prepared by dissolving 0.4 g potassium 
dihydrogen phosphate in 300 ml deionised water that was determined to be 
nitrate free by chromatography.  The pH was adjusted to 3.5 using phosphoric 
acid. 
 
6.4  Standards 
 
A 10 mM stock nitrate standard was prepared in deionised water and stored at 
-70˚C.  From this a 2,000 µM working standard was prepared for use in each 
analytical run.  The standard was determined to be stable under these 






6.5  Internal quality control material 
 
Urine obtained from a single volunteer was used as the QC material.  This was 
stored in aliquots at -70˚C until use, and analysed in duplicate within each 
analytical run in order to generate imprecision data. 
 
6.6  Sample preparation 
 
Standards, urine samples and QC material were diluted 1:50 in nitrate free 
deionised water prior to injection onto the analytical column. 
 
6.7  Chromatography 
 
6.7.1  Chromatographic system and setup 
 
The chromatographic system consisted of a solvent delivery system, 
programmable autosampler and ultraviolet detector (Waters 2478, Waters, 
Watford, UK).  100 µL of the diluted sample was injected onto the column for 
chromatography.  Signals were detected at a wavelength of 205 nm, with an 







6.7.2  Analytical column 
 
The analytical column was a Gemini phenyl, 3 µm, 4.6 x 150 mm, protected 
by a 3 x 4 mm guard column.  The ambient temperature in the laboratory was 
maintained at a constant level in order to ensure stability of retention times. 
 
6.7.3  Mobile phase 
 
The mobile phase, prepared as described, was maintained at room 
temperature and pumped through the analytical column at a flow rate of 0.75 
ml/minute.  The mobile phase was recycled in order to allow a larger number 
of samples to be analysed in a single run without having to prepare overly 
large volumes of the mobile phase.  This was not found to cause any problem 
with interfering peaks, even in large runs. 
 
6.8  Calculation of results 
 
Quantification was done by the method of external standardisation on the 
basis of peak heights as the nitrate peak was completely resolved at baseline 
and the peak consistently sharp and well defined.  Nitrate concentration was 
calculated by dividing the peak height of analyte in the (unknown) sample by 
that in the calibration standard and multiplying by the known concentration in 
the standard.  A single level calibration was selected owing to the linearity of 






6.9  Resultant chromatographic profiles 
 
The peak corresponding to nitrate was completely resolved from all other 
peaks, eluting at 6 minutes.  Chromatographic profiles corresponding to a 


















6.10  Analytical validation 
 
6.10.1  Linearity 
 
The detector response was determined to be linear up to 4,000 µM for nitrate 
under the conditions described.  Calibration curve and linear regression 
equation for nitrate are shown in figure 6.2.  These were determined by 
preparing sequential dilutions from a stock standard and subjected to the full 
analytical procedure.  The values on the y axes represent the detector 
response.  The correlation coefficient was > 0.999. 
 
 





6.10.2  Limits of detection and quantification 
 
Limit of detection was defined as 3 times the chromatographic baseline noise 
from a sample blank, and was determined to be 25 µmol/L.  The lower limit 
of quantification was defined as 10 times the signal-to-noise ratio, and was 
determined to be 83 µmol/L.  The lower limit of quantification is significantly 
lower than the concentrations commonly encountered in biological samples. 
 
6.10.3  Recovery 
 
Accuracy was assessed by determining the recovery of nitrate from spiked 
urine samples.  Increasing concentrations of nitrate were added to aliquots of 
a urine pool, and the recovery calculated following subtraction of the basal 
concentration.   This experiment was performed in triplicate, and the mean 






Mean (SD), µmol/L 
Calculated recovery 
Mean (SD), % 
0 1375 (35)  
864 2222 (59) 98.0 (6.2) 
1729 3000 (75) 94.0 (4.3) 
 
Table 6.1:  Recovery of nitrate from spiked urine samples (n = 3) 
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6.10.4  Precision 
 
6.10.4.1  Intra-assay variation 
The intra-assay CV was determined by analysing 5 aliquots of a single urine 
pool within a single batch.  Each aliquot was subjected to the described 
process, and so the data represent the imprecision of the whole analytical 
procedure.  The results from this are shown in table 6.2. 
 








CV, % 3.1 
   







6.10.4.2  Inter-assay variation 
The in-house QC material was analysed in duplicate in each batch.  8 pairs of 
QC duplicates were used to determine imprecision.  The data for these are 
shown in table 6.3.  Analytical variance (SDA
2) was calculated from the 
difference between each pair of duplicates according to the formula: 
SDA
2 = Σ d2/2N 
where d is the difference between each duplicate pair and N is the number of 
duplicate pairs.  Inter-assay CV was calculated from this variance, and was 
determined to be 2.8%. 
 
Pair no Sample 1, µmol/L Sample 2, µmol/L 
1 935 887 
2 854 879 
3 997 934 
4 851 889 
5 838 866 
6 859 846 
7 846 850 
8 874 856 
 






6.11 Comparison with Griess colorimetric assay 
 
6.11.1  Griess assay method 
 
Urine specimens from the knee arthroplasty study described in chapter 8 were 
analysed for nitrate concentration using both the currently described HPLC 
method and a commercially available colorimetric kit (Cayman Chemicals 
Item no 780001, Cambridge, UK).  This was performed according to the 
manufacturer’s instructions.  The method involves the initial reduction of 
nitrate to nitrite, the reaction of nitrite with sulfanilamide and subsequent 
reaction with naphthyl-ethylenediamine to form a purple coloured azo 
product which is measured spectrophotometrically at 540 nm.  The method 
displays intra- and interassay variations of 2.7% and 3.4% respectively.   
 
6.11.2  Method comparison 
 
108 urine specimens were subjected to analysis by both the HPLC and Griess 
methods.  There was a strong correlation between the methods (R2 = 88.3%), 










The Griess assay yielded consistently lower results than those from the HPLC 
assay, with the Griess results lower by a mean of 37.7%.  This constant bias is 





Figure 6.4:  Bland-Altman plot of HPLC and Griess nitrate methods 
 
6.12  Discussion 
 
The simplified HPLC method described in this chapter permits quantification 
of nitrate in urine with very straightforward sample preparation.  Interference 
from strongly retained late-eluting peaks was occasionally found to be a 
problem, but this was overcome by allowing an approximately 30 minute gap 
between sample injections after every 10 injections or so.  Another approach 
would be to programme a solvent flush after elution of the nitrate peak, 
something that would be possible using a programmable solvent delivery 
system.   
 
In common with other method comparisons between chromatographic and 
Griess methods, the Griess assay was found to under-recover nitrate 
compared with chromatography by a magnitude similar to that previously 
described254,255.  It has been speculated that this results either from the 
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incomplete reduction of nitrate to nitrite, or incomplete determination of the 
reduction recovery rate254.  Certainly, it suggests a systematic error, possibly 
resulting from the factors already mentioned or a problem in calibration.  
Methodological differences are highlighted by examination of supposedly 
“basal” nitrate concentrations in urine showing marked variability254.  
Creatinine adjusted values in the basal state for patients enrolled in the knee 





Other analytical methods 
 
7.1  Serum C-reactive protein (CRP) 
 
Serum CRP was measured in the routine biochemistry laboratories at 
Gartnavel General Hospital and the Western Infirmary, Glasgow on an Abbot 
Architect analyser (Abbot Park, Illinois).   The principle of the method is latex 
agglutination based on an antigen-antibody reaction, agglutination being 
detected as an absorbance change at 572 nm.  The intra and inter-assay CVs 
were < 1.0% and 2.1% respectively, and the assay performed satisfactorily in 
the relevant UK National External Quality Assessment Service (UK-NEQAS) 
scheme (Wolfson Laboratories, Birmingham). 
 
7.2  Serum albumin 
 
Serum albumin was measured in the routine biochemistry laboratories at 
Gartnavel General Hospital and the Western Infirmary, Glasgow on an Abbot 
Architect analyser (Abbot Park, Illinois).  The principle of the method is the 
binding of bromocresol purple to albumin to form a coloured complex, with 
absorbance at 604 nm proportional to the albumin concentration.  The intra 
and inter-assay CVs were all < 1.0%, and the assay performed satisfactorily in 







7.3  Serum urea 
 
Serum urea was measured in the routine biochemistry laboratories at 
Gartnavel General Hospital and the Western Infirmary, Glasgow on an Abbot 
Architect analyser (Abbot Park, Illinois).   The method is based on a series of 
enzymatic reactions with consumption of nicotinamide adenine dinucleotide 
(NADH) being detected as a reduction in absorbance at 340 nm.  The intra and 
inter-assay CVs were < 1.5% and < 2.0% respectively, and the assay performed 
satisfactorily in the relevant UK-NEQAS scheme. 
 
7.4  Serum and urine creatinine 
 
Serum and urine creatinine were measured in the routine biochemistry 
laboratories at Gartnavel General Hospital and the Western Infirmary, 
Glasgow on an Abbot Architect analyser (Abbot Park, Illinois).   The assay is a 
kinetic Jaffe method, the reaction of creatinine with alkaline picrate being 
detected as an absorbance change at 500 nm.  The intra and inter-assay CVs 
were < 1.0% and < 4.0% respectively, and the assays performed satisfactorily 
in the relevant UK-NEQAS scheme.   As previously described in chapter 3, 
eGFR was calculated from the serum creatinine results using the 4 variable 
MDRD equation242. 
 
7.5  Serum glucose 
 
Serum glucose was measured in the routine biochemistry laboratories at 
Gartnavel General Hospital and the Western Infirmary, Glasgow on an Abbot 
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Architect analyser (Abbot Park, Illinois).   The method is based on a series of 
enzymatic reactions starting with hexokinase, the production of NADH being 
detected as an absorbance change at 340 nm.  The intra and inter-assay CVs 
were all < 1.0%, and the assay performed satisfactorily in the relevant UK-
NEQAS scheme. 
 
7.6  Plasma insulin 
 
Plasma insulin was measured in the routine biochemistry laboratory at 
Glasgow Royal Infirmary on an Abbot Architect analyser (Abbot Park, Illinois).   
The assay is a one-step immunoassay with chemiluminescence detection.  The 
intra and inter-assay CVs were < 3.5% and < 4.7% respectively, and the assay 
performed satisfactorily in the Randox International Quality Assessment 
Scheme (RIQAS). 
 
7.7  Serum alanine aminotransferase (ALT) 
 
Serum ALT was measured in the routine biochemistry laboratories at 
Gartnavel General Hospital and the Western Infirmary, Glasgow on an Abbot 
Architect analyser (Abbot Park, Illinois).   The assay is based on a series of 
enzymatic reactions, ALT in the sample catalyzing the deamination of alanine.  
Ultimately, NADH is consumed, being detected as a reduction in absorbance 
at 340 nm.  The intra and inter-assay CVs were < 2.0% and < 4.8% respectively, 







7.8  Serum bilirubin 
 
Serum bilirubin was measured in the routine biochemistry laboratories at 
Gartnavel General Hospital and the Western Infirmary, Glasgow on an Abbot 
Architect analyser (Abbot Park, Illinois).   The principle of the method is the 
binding of bilirubin to a diazo reagent, the azobilirubin product being 
detected as an absorbance change at 548 nm.  The intra and inter-assay CVs 
were < 1.0% and < 2.0% respectively, and the assay performed satisfactorily in 
the relevant UK-NEQAS scheme. 
 
7.9  Haemoglobin (for erythrocyte lysates) 
 
The haemoglobin concentration in erythrocyte lysate preparations was 
measured in the biochemistry laboratory at Glasgow Royal Infirmary using a 
Sysmex KX-21N analyser (Sysmex, Canada).   The intra and inter-assay CVs 





Knee arthroplasty study design 
 
The aim of this study was to investigate the response of plasma 
dimethylarginines to a significant inflammatory response as seen following 
surgery, and to relate this to the urinary excretion of dimethylamine (DMA) as 
a marker of ADMA metabolism, and to the excretion of urinary nitrate as a 
marker of NO production.  The elective surgery model was chosen as it allows 
examination from a non-inflamed baseline, thus enlightening the temporal 
relationship between inflammation and changes in ADMA concentration. 
 
8.1  Ethical approval 
 
Approval of the study protocol was granted by the Glasgow Royal Infirmary 
Research Ethics Committee.  Copies of ethical committee and management 
approval can be seen in appendix 3, along with copies of the patient 
information sheet and consent form. 
 
8.2  Inclusion and exclusion criteria 
 
Patients undergoing elective knee joint arthroplasty for osteoarthritis at 
Gartnavel General Hospital were considered suitable for inclusion.  Patients 
with joint disease secondary to inflammatory arthropathies such as 
rheumatoid arthritis were considered unsuitable as they would be expected to 
exhibit a baseline (chronic) inflammatory response.   
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Two patients were subsequently excluded from the study in the immediate 
post-operative period, one following an acute coronary syndrome and one 
following a pulmonary embolism. 
 
Suitable patients were identified and their consent for participation obtained 
during attendance at the pro-operative assessment clinic by Dr David Reid or 
myself.  Copies of the patient information sheet and consent form can be seen 
in appendix 4.   
 
8.3  Specimen collection 
 
Venous blood and urine specimens were collected according to the protocol 
outlined below.   In general patients had their evening meal around 18:00 hrs, 
with urine specimens collected between 12 and 15 hours later.  This 
consistency was felt to minimise the variability attributable to DMA and 
nitrate excretion from ingested food.  In addition, patients did not consume 
food known to contribute significantly to urinary DMA excretion, which, as 
previously discusses, is largely confined to certain types of fish and shellfish. 
 
Day 0 (baseline) 
Urine collected during fasting period into a plain universal container for DMA 
and nitrate. 
Blood collected under fasting conditions into serum separator tube (SST) for 
routine biochemistry tests and oxalate tube for glucose. 
Blood collected by anaesthetist at time of induction of anaesthesia into a 




12 hours post-operatively 
Blood collected into heparinised tube for dimethylarginines. 
 
Day 1 to 5 post-operatively (daily, in ward) 
Urine collected during morning following overnight fast for DMA and nitrate. 
Blood collected fasting into SST and oxalate tubes for routine biochemistry 
tests and glucose. 
Blood collected into heparinised blood tube for dimethylarginines. 
 
3 months post-operatively (at out-patient clinic) 
Blood collected into heparinised blood tube for dimethylarginines. 
 
8.4  Specimen handling 
 
Blood and urine specimens were transported to the biochemistry laboratory 
within 1 hour of collection.  SST and oxalate tubes for routine biochemistry 
tests were handled according to established procedures in the routine 
laboratory.  Urine specimens were frozen without delay at -70˚C.  The 
heparinised blood tube was centrifuged (500 g, 4˚C, 10 minutes) and the 







8.5  Participant demographics 
 
38 participants were recruited and completed the study.  There were 14 
males and 24 females with an age range of 55 to 81 years.  9 of these patients 
had a pre-operative diagnosis of type 2 diabetes mellitus, treated either by 
dietary control or oral hypoglycaemic drugs.  All underwent total knee joint 
arthroplasty using a standard medial parapatellar surgical approach.  Patients 
underwent anaesthesia either by general anaesthetic or spinal anaesthesia 
with sedation.  Intravenous fluids were administered as part of routine patient 
care during the first 24 hours post-operatively.  Intra-operative blood loss was 
minimised by use of a tourniquet.  Nonetheless, seven patients were judged 
to require a blood transfusion post-operatively by the surgical team caring for 
them, based on haemoglobin measurement on the second post-operative day.   
 
10 patients had progressed sufficiently to be discharged home on the fourth 
post-operative day, and so do not have measurements available for day 5.  
The remainder stayed to at least the fifth post-operative day.  It was possible 
to obtain specimens from 26 patients 3 months post-operatively, when they 
were attending the out patient clinic for review. 
 
Participant demographics, diabetes status, details of blood transfusion and 








8.6  Statistical methods 
 
The Anderson-Darling test was used to assess the distribution of data, with p < 
0.05 taken to indicate non-normal distribution.  Where relevant and possible, 
logarithmic transformation was used to permit T-testing between paired 
groups of data.  Otherwise the Mann Whitney U test was used, with p < 0.05 
chosen for statistical significance. 
 
The Friedman test was used to examine for changes in parameters measured 
repeatedly across the study period, with p < 0.05 taken to indicate statistical 
significance.  The Mann Whitney U test was used to compare data from 2 time 
points to determine at which points the changes occurred. 
 
To determine the association between two variables, Spearman rank 
correlation (rs) was used, unless otherwise stated, more or less throughout 
given that almost all of the data were non-normally distributed.  Scatter plots 




Plasma dimethylarginines during the inflammatory response following 
elective knee arthroplasty 
 
9.1  Changes in acute phase reactants 
 
9.1.1  Serum C reactive protein (CRP) 
 
CRP increased significantly and rapidly in the post-operative period, indicating 
a significant inflammatory response.  The CRP peaked at days 2 – 3 post-
operatively, and was still significantly higher than baseline at day 5.  The 
median and inter-quartile CRP concentrations can be seen in table 9.1.  The 
Friedman test was used to establish the significance of the change in CRP, and 
found this to be highly significant (p < 0.0001).  The Mann Whitney U test was 
used to establish the significance of changes between days, finding significant 
changes between days 0 and 1, and 1 and 2 (p < 0.0001), with a plateau 
between days 2 and 3 (p = 0.91).   By day 5, CRP was reducing from its peak 
(day 2 vs 5, p < 0.01).  By 3 months, CRP had returned to baseline 
concentrations. 
 
9.1.2  Serum albumin 
 
Serum albumin concentration decreased significantly during the acute phase 
reaction, with the Friedman test demonstrating a highly significant change (p 
< 0.0001).  Mann Whitney U test comparisons showed a significant change 
between days 0 and 1 (p < 0.0001), with a trend to a further decrease 
between days 1 and 2 (p = 0.08), and a plateau thereafter to day 5 (p non 
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significant).  By 3 months, albumin had returned to baseline concentrations.  
Table 9.2 shows the median and inter-quartile albumin concentrations across 
the study period. 
 
The observed changes in CRP and albumin were therefore taken to confirm a 
significant post-operative inflammatory response. 
 
Time point CRP concentration, mg/L 
Day 0 2.7 (1.5 – 4.4) 
Day 1 53 (39 – 79) 
Day 2 169 (112 – 230) 
Day 3 191 (121 – 229) 
Day 4 135 (93 – 178) 
Day 5 (n = 28) 107 (74 – 136) 
3 months (n = 26) 3.0 (1.7 – 5.2) 
 









Time point Albumin concentration, g/L 
Day 0 39 (37 – 40) 
Day 1 33 (31 – 35) 
Day 2 31 (29 – 34) 
Day 3 31 (29 – 32) 
Day 4 30 (29 – 32) 
Day 5 (n = 28) 31 (27 – 32) 
3 months (n = 26) 39 (37 – 41) 
 
Table 9.2:  Median (inter-quartile range) albumin concentrations during 
study period 
 
9.2  Fasting glucose and insulin resistance  
 
Patients not known to be diabetic (n = 29) underwent measurements of fasting 
glucose and insulin pre-operatively and on each morning post-operatively in 
order to assess the effect of their inflammatory response on insulin 
sensitivity.  As previously discussed, insulin resistance may have adverse 
effects on DDAH activity and ADMA metabolism.   
 
There was a significant change in fasting glucose across the study period 
(Friedman p < 0.0001).  The Mann Whitney U test determined this to be a 
significant increase between days 0 and 1 (7.7 vs 5.5 mmol/L, p < 0.0001).  
This rise from baseline remained significant to day 4 post-operatively (day 0 
vs 4, p = 0.03), with a non-significant difference between days 0 and 5 (p = 
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0.2).  The median and inter-quartile range glucose concentrations are shown 
in table 9.3.  Fasting insulin demonstrated a significant change across the 
study period (Friedman p < 0.001).  In a similar pattern to glucose, this was 
evident between days 0 and 1 (13.9 vs 7.2 mU/L, p < 0.001), and remained 
higher than baseline to the end of the study period (day 0 vs 5, p = 0.01).  The 
homeostasis model assessment-insulin resistance (HOMA-IR) was calculated as 
a marker of insulin resistance258, and demonstrated a significant change 
(Friedman p < 0.0001).  This was significantly higher at day 1 (4.64 vs 1.64), 
and remained significantly higher to the end of the study period (day 5 vs 0, p 
= 0.02).  Median and inter-quartile range insulin concentrations and HOMA-IRs 
are also shown in table 9.3. 
 
Spearman correlation showed no significant correlations between the rise in 
CRP and day 1 glucose concentration or HOMA-IR (p = 0.56 and 0.99 
respectively). 
 
Day Glucose, mmol/L Insulin, mU/L HOMA-IR 
0 5.5 (5.0 – 6.0) 7.2 (5.6 – 10.2) 1.64 (1.32 – 2.68) 
1 7.7 (6.4 – 8.2) 13.9 (8.1 – 22.2) 4.64 (2.55 – 7.89) 
2 6.5 (5.7 – 7.1) 11.0 (8.5 – 19.9) 3.20 (2.34 – 6.76) 
3 6.2 (5.8 – 6.5) 12.0 (9.9 – 13.7) 3.31 (2.60 – 4.26) 
4 6.0 (5.3 – 6.6) 13.1 (8.9 – 16.0) 3.25 (2.32 – 4.34) 
5 (n = 21) 5.8 (5.3 – 6.4) 10.3 (7.9 – 13.1) 2.56 (1.98 – 3.39) 
  
Table 9.3:  Median (inter-quartile range) fasting glucose, insulin and 
HOMA-IR during study period (n = 29) 
148 
 
9.3  Plasma ADMA during the acute inflammatory response 
 
Plasma ADMA concentration decreased rapidly and significantly during the 
acute inflammatory response (Friedman p < 0.0001).  The nadir concentration 
was reached on day 2 post-operatively, by which point a median reduction of 
31% had occurred (0.43 vs 0.68 µmol/L).  However, by 12 hours post-op the 
reduction was already seen to be significant (p < 0.0001).  The plasma ADMA 
concentration was recovering by day 4 post-op, with a significant increase 
seen between days 2 and 4 (p < 0.0001).  For patients who had samples from 
both days 4 and 5 available (n = 28), a further significant increase was seen 
between days 4 and 5 (p = 0.025), such that by day 5 the ADMA concentration 
had returned to baseline levels (day 0 vs 5, p = 0.56).  Table 9.4 shows the 
median and inter-quartile range ADMA concentrations, and figure 9.1 shows 
the data as box plots. 
 
No significant correlation between ADMA concentration and eGFR was found 
either at baseline (rs = -0.06, p = 0.71), as shown in figure 9.2, or at the peak 











Time point ADMA concentration, µmol/L 
Day 0 0.62 (0.54 – 0.65) 
12 hours 0.48 (0.43 – 0.54) 
Day 1 0.43 (0.40 – 0.45) 
Day 2 0.43 (0.39 – 0.47) 
Day 3 0.49 (0.45 – 0.53) 
Day 4 0.55 (0.51 – 0.62) 
Day 5 (n = 28) 0.61 (0.57 – 0.64) 
3 months (n = 26) 0.58 (0.52 – 0.59) 
 
Table 9.4:  Median (inter-quartile range) ADMA concentrations during study 
period 
 





Figure 9.2:  Relationship between plasma ADMA and eGFR on day 0 
 
The relationship between the inflammatory response and ADMA concentration 
was further examined at baseline and at the peak of the inflammatory 
response, using Spearman rank correlation. No significant correlation was 
found between ADMA and CRP concentrations at baseline in the non-inflamed 
state (rs = -0.22, p = 0.19).  To investigate whether the magnitude of the 
inflammatory response was reflected by the change in ADMA concentration, 
the relationship between the change in CRP concentration, i.e. the peak 
minus baseline values, and percent change in ADMA concentration was sought.  
A relatively weak correlation of borderline statistical significance was found 







Figure 9.3:  Relationship between ADMA and CRP concentrations on day 0 
 
 





9.4  Plasma SDMA during the acute inflammatory response 
 
In contrast to ADMA, the plasma SDMA concentration showed no significant 
changes during the study period (Friedman p = 0.638).  The median and inter-
quartile range concentrations are shown in table 9.5, with the data illustrated 
as box plots in figure 9.5.  The SDMA concentration was significantly 
correlated with eGFR at baseline in the non-inflamed state (rs = -0.47, p = 
0.003), as shown in figure 9.6.  This relationship remained unaltered during 
the peak of inflammation on day 2 (rs = -0.59, p < 0.001), as shown in figure 
9.7. 
 
The differential responses of the two dimethylarginines is reflected in the 
ADMA:SDMA ratio which decreases significantly (Friedman p < 0.0001) in a 














Time point SDMA concentration, µmol/L ADMA:SDMA ratio 
Day 0 0.48 (0.42 – 0.56) 1.28 (1.10 – 1.43) 
12 hours 0.49 (0.40 – 0.60) 1.02 (0.82 – 1.16) 
Day 1 0.49 (0.42 – 0.55) 0.88 (0.74 – 0.99) 
Day 2 0.45 (0.40 – 0.57) 0.89 (0.77 – 1.07) 
Day 3 0.48 (0.42 – 0.55) 1.02 (0.89 – 1.16) 
Day 4 0.49 (0.42 – 0.55) 1.14 (0.99 – 1.37) 
Day 5 (n = 28) 0.48 (0.43 – 0.59) 1.20 (1.03 – 1.40) 
3 months (n = 26) 0.45 (0.39 – 0.48) 1.27 (1.14 – 1.45) 
 
Table 9.5:  Median (inter-quartile range) SDMA concentrations and 
ADMA:SDMA ratios during study period 




Figure 9.6:  Correlation between plasma SDMA and eGFR on day 0 
 
 





9.5  Serum sodium, urea and creatinine during the acute inflammatory 
response 
 
In order to investigate the possibility of dilution as a cause for the reduction 
in plasma ADMA concentration, serum sodium and urea concentrations were 
measured during the study period.  The inflammatory response is associated 
with promotion of water retention, probably through the enhanced action of 
the anti-diuretic hormone arginine vasopressin.  Significant water retention 
and dilution would be expected to have effects on the serum concentrations 
of sodium and urea, with mild hyponatraemia a common finding in 
hospitalised patients.   
 
Serum creatinine concentrations showed no significant changes across the 
study period, suggesting no major disturbance in renal function.  Serum urea 
showed a significant change over the study period (Friedman p < 0.0001).  
This was a modest in absolute terms, amounting to a median 12.7% reduction 
(4.4 vs 5.6 mmol/L, p = 0.03).  By day 3 this had returned to baseline 
concentrations.  No significant change was evident at day 1 post-op (5.5 vs 5.6 
mmol/L, p = 0.77).  Serum sodium concentration changed significantly during 
the study period (Friedman p < 0.0001), with a modest median 2.2% reduction 
evident at day 1 (136 vs 139 mmol/L, p < 0.0001).  This remained reduced 
from baseline for the duration of the study (day 5 vs 0, p = 0.02), returning to 
baseline concentrations 3 months post-operatively (p = 0.67).  Median and 









Time point Sodium, mmol/L Urea, mmol/L Creatinine, µmol/L 
Day 0 139 (138 – 140) 5.6 (4.6 – 6.8) 78 (69 – 85) 
Day 1 136 (134 – 137) 5.5 (4.4 – 6.8) 77 (67 – 83) 
Day 2 137 (135 – 138) 4.4 (3.4 – 6.1) 78 (66 – 87) 
Day 3 137 (135 – 139) 4.8 (3.9 – 7.1) 77 (68 – 87) 
Day 4 138 (135 – 140) 5.1 (4.6 – 6.7) 77 (65 – 86) 
Day 5 138 (136 – 140) 5.5 (4.8 – 6.9) 77 (67 – 83) 
3 months 140 (138 – 141) 6.2 (4.9 – 7.6) 81 (75 – 87) 
 
Table 9.6:  Median (inter-quartile range) serum sodium, urea and 
creatinine concentrations during study period 
 
9.6  Plasma arginine and homoarginine during the acute inflammatory 
response 
 
Arginine concentrations changed significantly across the study period 
(Friedman p < 0.0001).  Mann Whitney U test comparisons showed a significant 
reduction which was evident at 12 hours post-op (33 vs 48 mmol/L, p < 
0.0001) and remained significantly lower than baseline until day 3 (p = 0.004 
vs day 0).  This was a similar pattern to ADMA, such that there was minimal 
change in the arginine:ADMA ratio.  The arginine:ADMA ratio was lower at 12 
hours post-op, achieving borderline significance (70 vs 84, p = 0.05); however 





Homoarginine changed significantly across the study period (Friedman p < 
0.0001).  Mann Whitney U test comparisons revealed a significant change to 
have occurred by day 2 post-op (1.05 vs 1.48 µmol/L, p = 0.001).  
Homoarginine remained significantly lower than baseline until day 5 (p < 
0.0001 vs day 0), and had recovered to baseline at 3 months (p = 0.22).  
Median and inter-quartile range arginine, arginine:ADMA ratio and 









Day 0 48 (41 – 60) 84 (68 – 98) 1.48 (1.10 – 1.91) 
12 hours 33 (28 – 43) 70 (58 – 90) 1.33 (1.03 – 1.78) 
Day 1 32 (24 – 39) 76 (63 – 91) 1.28 (0.96 – 1.73) 
Day 2 31 (24 – 43) 76 (52 – 92) 1.05 (0.80 – 1.51) 
Day 3 36 (30 – 50) 78 (67 – 97) 0.78 (0.68 – 1.26) 
Day 4 49 (40 – 64) 88 (71 – 108) 0.81 (0.65 – 1.23) 
Day 5 (n = 28) 46 (36 – 60) 74 (60 – 102) 0.95 (0.66 – 1.15) 
3 months (n = 
26) 
52 (38 – 67) 93 (67 – 126) 1.29 (1.03 – 1.66) 
 
Table 9.7:  Median (inter-quartile range) arginine, arginine:ADMA ratio and 





9.7  Summary of findings 
 
The post-operative course was characterised by a significant inflammatory 
response with evidence of an associated insulin resistant state.  Plasma ADMA 
concentration decreased significantly and rapidly during the early phase of 
the inflammatory response, recovering to baseline concentrations by day 5 
post-op.  The magnitude of the inflammatory response, as reflected by CRP 
concentration, was weakly associated with the magnitude of the reduction in 
plasma ADMA concentration.  In contrast, plasma concentrations of the closely 
related compound SDMA showed no significant changes during the study 
period, and were closely related to renal function.   Although modest changes 
in serum sodium and urea concentrations were seen, these are unlikely to 
represent a significant contribution of dilution to the changes in ADMA.  
Plasma arginine concentration changed similarly to ADMA during the post-
operative period.  Homoarginine concentration decreased more slowly and 
progressively, and remained lower than baseline at day 5 post-op at which 




Erythrocyte free ADMA concentrations during the inflammatory response 
following elective knee arthroplasty 
 
10.1  Introduction 
 
Erythrocytes contain substantial quantities of ADMA, mainly incorporated in 
methylated proteins.  This is largely in proteins other than haemoglobin259-261, 
and incubation of erythrocyte lysates at 37˚C yields increases in free ADMA 
from the action of proteases, something which can inhibited by protease 
inhibitors and incubation at 4˚C259-261.  However, erythrocytes also contain a 
certain concentration of free ADMA within their cytoplasm, which has been 
determined to be up to 2 times the concentration found in plasma261.  This 
concentration is made possible by the expression of system y+ cationic amino 
acid transporters (CAT) which have been well characterised on rat 
erythrocytes262, and in humans have been implicated in the erythrocyte 
transport of basic amino acids such as arginine and MMA263,264.  The 
relationship between plasma and free erythrocyte concentrations of ADMA is 
not clear, but Davids et al have recently shown a correlation between them in 
patients with critical illness, but not in healthy controls261.  The authors 
speculate that increased expression of CATs in the critically ill patient could 
account for the correlation, and cite the up-regulation of CATs in other 
disease states such as heart failure, renal failure and pre-eclampsia in support 
of this hypothesis262,264,265.  How this could occur in critical illness is unclear, 
although CAT-2B transporters can be up-regulated by inflammatory 
cytokines266.  Whether human erythrocytes have the capacity to metabolise 
ADMA is controversial, with mixed results in published studies.  Experimental 
evidence for DDAH-mediated catabolism has been offered from studies in rat 
and human erythrocytes259,267,268; however other studies have failed to 
demonstrate evidence of DDAH activity260,261. 
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In the present study free erythrocyte concentrations were determined in knee 
arthroplasty participants to determine their relationship to plasma 
concentrations during the inflammatory response, and therefore to determine 
their likely relevance to the acute changes in plasma ADMA concentration 
described in the previous chapter. 
 
10.2  Methods 
 
ADMA concentrations were measured in the lysates of erythrocytes taken pre-
operatively and at days 1, 2 and 3 months post-operatively.  After exclusion of 
subjects who underwent blood transfusion, this left 20 subjects with available 
samples.  Erythrocyte ADMA was measured using the method described in 
chapter 2 and the concentrations expressed as a ratio to haemoglobin 
concentration in the lysate; this latter step was employed to correct for 
errors introduced during the pipetting of cellular material.  
 
The Friedman test was used to determine whether significant changes in 
erythrocyte ADMA occurred over serial samples.  Spearman rank correlation 
was used to examine the relationship between plasma and erythrocyte 
concentrations where the data were non-normally distributed.  Statistical 
analysis was done using Minitab statistical software. 
 
10.3  Results 
 
Median and inter-quartile range erythrocyte ADMA concentrations, expressed 
as a ratio to haemoglobin, are shown in table 10.1.  Comparisons between pre 
and post-operative samples, using the Friedman test showed no significant 




Time point Erythrocyte ADMA, nmol/g Hb 
Day 0 30.1 (24.1 – 39.4) 
Day 1 25.6 (18.9 – 37.3) 
Day 2 26.7 (23.6 – 38.3) 
3 months 32.1 (23.9 – 37.0) 
 
Table 10.1:  Median (inter-quartile range) erythrocyte free ADMA 
concentrations during the inflammatory response 
 
No significant correlations between erythrocyte and plasma ADMA 
concentrations were seen, both pre-operatively, in the absence of an 
inflammatory response or post-operatively at the peak of the inflammatory 
response (p = 0.85 on day 0; p = 0.28 on day 2).  These are shown in figures 





Figure 10.1:  Correlation between erythrocyte and plasma ADMA 
concentrations on day 0 
 
Figure 10.2:  Correlation between erythrocyte and plasma ADMA 




10.4  Summary of findings 
 
Concentrations of free ADMA within erythrocytes did not change significantly 
on development of the inflammatory response.  Pre-operatively and at the 
peak of inflammation on day 2, no correlations were found between 
erythrocyte and plasma ADMA concentrations.  Therefore no evidence was 
found to suggest that the abrupt decrease in plasma ADMA concentration 
which occurred during the inflammatory response was related to increased 




Urinary excretion of dimethylamine, ADMA and nitrate during the 
inflammatory response following elective knee arthroplasty 
 
11.1  Introduction 
 
Urine measurements were performed on the subjects who had a full set of 
urine samples available to day 5 post-op (n = 20).  As previously described, 
these were collected fasting pre-operatively and on each post-op morning.  
Concentrations of dimethylamine (DMA), dimethylarginines and nitrate were 
measured using the methods described in the relevant chapters, and 
expressed as ratios to creatinine. 
 
11.2  Urine DMA during the acute inflammatory response 
 
11.2.1  Urine DMA excretion 
 
Urine DMA concentrations, expressed as ratios to creatinine, across the study 
period are shown in table 11.1.  The Friedman test revealed a significant 
change over the study period (p = 0.001).  Mann Whitney U test comparisons 
revealed a significant increase in DMA excretion at day 5 compared with 
baseline (median 105 vs 53 µmol/mmol creat, p = 0.003), but no significant 
differences between concentrations on days 1 to 4 versus baseline.  There was 




There was no significant correlation between the magnitude of the 
inflammatory response and the magnitude of increase in DMA excretion at day 
5 (rs = 0.14, p = 0.54), as shown in figure 11.1. 
 
Time point DMA, µmol/mmol creatinine 
Day 0 53 (44 – 87) 
Day 1 59 (41 – 81) 
Day 2 46 (38 – 97) 
Day 3 59 (48 – 108) 
Day 4 60 (44 – 82) 
Day 5 105 (63 – 155) 
 






Figure 11.1:  Relationship between changes in CRP concentration and DMA 
excretion 
 
11.2.2  Relationship between concentrations of urinary DMA and ADMA 
 
Urine DMA and ADMA concentrations were significantly correlated at baseline, 
in the non-inflamed state (rs = 0.66, p = 0.002), as shown in figure 11.2.  This 
relationship was weakened, though remained significant, on day 1 post-op (rs 
= 0.54, p = 0.01), but was lost by day 2, at the peak of the inflammatory 
response (rs = 0.08, p = 0.72), as shown in figure 11.3.  By day 5 urine DMA 
and ADMA concentrations were once again correlated (rs = 0.42, p = 0.07), as 





Figure 11.2:  Relationship between urinary concentrations of DMA and 
ADMA on   day 0 
 
 
Figure 11.3:  Relationship between urinary concentrations of DMA and 




Figure 11.4:  Relationship between urinary concentrations of DMA and 
ADMA on  day 5 
 
No significant correlation was seen between plasma ADMA concentration and 
the urinary excretion of DMA at baseline (day 0: rs = -0.12, p = 0.62).  
Similarly, no correlations were noted on any of the post-op days. 
 
11.3 Urine ADMA and SDMA excretion during the acute inflammatory 
response 
 
11.3.1  Urine ADMA excretion 
 
Urine ADMA concentrations, expressed as ratios to creatinine, across the study 
period are shown in table 11.2.  The Friedman test showed a significant 
change in ADMA concentrations across the study period (p < 0.0001).  Mann 
Whitney U test comparisons showed a difference between days 0 and 2 which 
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was of borderline statistical significance (p = 0.07).  As ADMA concentrations 
at day 0 were not normally distributed, the day 0 and 2 results were 
logarithmically transformed and were normally distributed following 
transformation (Anderson Darling test, day 0 p = 0.60, day 2 p = 0.22).  A 
paired T test on the log transformed results showed a significant difference (p 
= 0.008), confirming a significant reduction in urine ADMA at day 2 compared 
with day 0 (median 2.95 vs 3.95 µmol/mmol creatinine).  This represented the 
nadir of urine ADMA across the study period.  The Mann Whitney U test 
showed a significant increase in ADMA at day 4 compared with day 2 (median 
4.95 vs 2.95 µmol/mmol creatinine , p = 0.03), but no significant difference 
compared with day 0 (p = 0.28).  The ADMA on day 5 was significantly higher 
compared with day 2 (median 5.15 vs 2.95 µmol/mmol creatinine, p < 0.001), 
and showed a statistically borderline change compared with day 0 (Mann 
Whitney U test, p = 0.07).  Given their non-normal distribution, day 5 results 
were logarithmically transformed and found to normally distributed following 
transformation (Anderson Darling test, p = 0.68).  A paired T test on the log 
transformed results showed a significant difference (p = 0.007), confirming a 
significant increase in urine ADMA at day 5 compared with day 0 (median 5.15 
vs 3.95 µmol/mmol creatinine). 
 
At day 0, in the absence of an inflammatory response, plasma and urine ADMA 
concentrations were moderately, but non-significantly correlated (rs = 0.33, p 
= 0.16), as shown in figure 11.5.  There was a significant correlation seen on 
day 2 post-op      (rs = 0.51, p = 0.02), as shown in figure 11.6.  However no 
correlations were seen on any of the other post-op days (days 1, 3, 4 and 5: p 












ADMA:SDMA ratio  
Day 0 3.95 (3.15 – 4.88) 3.50 (2.63 – 4.30) 1.15 (0.98 – 1.22) 
Day 1 3.65 (3.10 – 5.08) 4.90 (3.88 – 5.85) 0.87 (0.67 – 1.02) 
Day 2 2.95 (2.02 – 4.55) 3.80 (2.92 – 5.03) 0.77 (0.66 – 1.00) 
Day 3 3.65 (2.18 – 4.75) 4.55 (2.88 – 5.40) 0.87 (0.78 – 0.99) 
Day 4 4.95 (2.25 – 6.80) 4.75 (3.43 – 6.00) 0.96 (0.89 – 1.15) 
Day 5 5.15 (3.53 – 6.43) 4.60 (4.08 – 5.48) 1.10 (0.89 – 1.29) 
  
Table 11.2:  Median (inter-quartile range) AMDA and SDMA:creatinine 
ratios and ADMA:SDMA ratios during study period 
 
 
Figure 11.5:  Relationship between plasma ADMA concentration and urine 




Figure 11.6:  Relationship between plasma ADMA concentration and urine 
ADMA: creatinine ratio on day 2 
 
11.3.2  Urine SDMA excretion 
 
The Friedman test showed a significant change in urine SMDA:creatinine ratio 
during the study period (p = 0.008).  Mann Whitney U test comparison showed 
a significant increase at day 1 (median 4.90 vs 3.50 µmol/mmol creatinine, p 
= 0.004).  This difference remained significant at days 3, 4 and 5 post-op 
compared with day 0 (p = 0.05, 0.03 and < 0.01 respectively).   
 
No significant correlations were seen between plasma SDMA concentrations 
and urine SDMA:creatinine ratios at day 0 (rs = 0.18, p = 0.45), as shown in 






Figure 11.7:  Relationship between plasma SDMA concentration and urine 
SDMA: creatinine ratio on day 0 
 
11.3.3  Relationship between urine ADMA and SDMA concentrations 
 
In spite of the differential changes in urine ADMA and SDMA excretions 
described, they remained very strongly correlated through the study period.  
The correlation at day 0 is shown in figure 11.8 (rs = 0.95, p < 0.001).  The 
relationship remained significant during the inflammatory response as 
illustrated by the values on day 2, in figure 11.9 (rs = 0.90, p < 0.001).  This 
demonstrates a similar relationship in the non-inflamed and inflamed states, 
and remains despite no similar correlations between the concentrations of 





Figure 11.8:  Relationship between urinary ADMA and SDMA concentrations 
on day 0 
 
 
Figure 11.9:  Relationship between urinary ADMA and SDMA concentrations 
on day 2 
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11.3.4  Urine ADMA:SDMA ratio 
 
The median and inter-quartile range ratio of ADMA to SDMA concentrations in 
urine are shown in table 11.2.  The Friedman test demonstrated a significant 
change across the study period (p < 0.0001).  The Mann Whitney U test 
confirmed a significant decrease at day 1 from baseline (median 0.87 vs 1.15, 
p = 0.0002).  The ratio remained lower than baseline at day 3 (p = 0.002), and 
returned to baseline levels by day 5 (median 1.10 vs 1.15, p = 0.84). 
 
The ADMA:SDMA ratios in plasma and urine were normally distributed, and so 
linear regression was used to determine their relationship.  A significant 
correlation was seen  at day 0, in the non-inflamed state (R2 = 0.77), as shown 
in figure 11.10.  Similarly significant correlations were seen between plasma 
and urine on each of the post-operative days, with day 2 illustrated in figure 
11.11, representing the peak of the inflammatory response (R2 = 0.93). 
 
Figure 11.10: Relationship between ADMA:SDMA ratios in plasma and urine 




Figure 11.11: Relationship between ADMA:SDMA ratios in plasma and urine 
on day 2  
 
11.3.5  Urine fractional excretions of ADMA and SDMA 
 
To gain further insight into the renal handling of ADMA and SDMA, their 
fractional excretions (FE) were calculated.  These were done according the 
formula: 
 
FE = (Urine “X” × Serum creatinine) / (Plasma “X” × Urine creatinine × 1000) 
 
where “X” is ADMA or SDMA in µmol/L, and serum and urine creatinine 




FEs are shown in table 11.3.  The Mann Whitney test revealed a significant 
increase in the FE of ADMA was seen on day 1 compared with day 0 (median 
0.72 vs 0.49, p = 0.001).  On the subsequent post-operative days no 
statistically significant differences compared with day 0 were noted, until day 
5 at which point the increase from day 0 was significant (median 0.58 vs 0.49, 
p = 0.01). 
 
A very similar pattern was seen for the FEs of SDMA.  The Mann Whitney test 
revealed a significant increase on day 1 compared with day 0 (median 0.79 vs 
0.54, p = 0.008).  On post-operative days 2 to 4 no statistically significant 
differences compared with day 0 were noted, until day 5 at which point the 
increase from day 0 was significant (median 0.61 s 0.54, p = 0.01). 
 
The FEs for ADMA and SMDA were found to be normally distributed, and so 
linear regression was used to examine their relationship.  A strong correlation 
was noted between the FEs of ADMA and SDMA at day 0 (R2 = 0.84), as seen in 
figure 11.12.  This association persisted on each of the post-operative days, 
with day 2 illustrated in figure 11.3 as representative of the inflammatory 











Time point ADMA fractional excretion SDMA fractional excretion 
Day 0 0.49 (0.41 – 0.57) 0.54 (0.44 – 0.64) 
Day 1 0.72 (0.55 – 0.94) 0.79 (0.52 – 0.88) 
Day 2 0.54 (0.46 – 0.62) 0.59 (0.54 – 0.67) 
Day 3 0.59 (0.43 – 0.75) 0.64 (0.50 – 0.81) 
Day 4 0.53 (0.45 – 0.76) 0.62 (0.52 – 0.71) 
Day 5 0.58 (0.53 – 0.73) 0.61 (0.59 – 0.82) 
 
Table 11.3:  Median (inter-quartile range) urinary fractional excretions of 
ADMA and SDMA during study period 
 
Figure 11.12:  Relationship between urinary fractional excretions of ADMA 




Figure 11.13:  Relationship between urinary fractional excretions of ADMA 
and SDMA on day 2 
 
11.4  Urine nitrate excretion during the acute inflammatory response 
 
Median and inter-quartile range concentrations of urine nitrate, expressed as 
ratios to creatinine, are shown in table 11.4.  The Friedman test suggested a 
change of borderline significance across the study period (p = 0.089).  The 
Mann Whitney U test suggested a decrease in nitrate concentrations at day 2 
compared with day 0, which just failed to reach statistical significance 
(median 55 vs 73 µmol/mmol creat, p = 0.086).  Closer examination of the 
data revealed the day 2 concentrations to be non-normally distributed 
(Anderson Darling test, p = 0.049), with normal distribution at day 0 (Anderson 
Darling, p = 0.13).  Logarithmic transformation failed to render the day 2 
concentrations normally distributed, thus the data were examined for 
outliers; following the removal of one data point which exceeded the mean by 
> 3 standard deviations, the data were normally distributed (Anderson 
Darling, p = 0.12).  Application of a paired T test to the resultant data 
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revealed a significant decrease in nitrate concentrations at day 2 compared 
with day 0 (mean 58 vs 90 µmol/mmol creat, p = 0.002).  By day 5 the nitrate 
excretion had returned to baseline levels (median 78 vs 73 µmol/mmol creat, 
p = 0.78). 
 
Time point Nitrate, µmol/mmol creat 
Day 0 73 (45 – 124) 
Day 1 61 (36 – 102) 
Day 2 55 (41 – 74) 
Day 3 58 (35 – 75) 
Day 4 65 (45 – 90) 
Day 5 78 (49 – 110) 
 












11.5  Summary of findings 
 
The urinary excretion of DMA, the major metabolite of ADMA catabolism, was 
unchanged during the early phase of the acute inflammatory response, 
suggesting that increased DDAH-mediated catabolism was not responsible for 
the early decrease in plasma ADMA concentration.  DMA excretion increased 
significantly at day 5 post-operatively, coinciding with the return of plasma 
ADMA concentration to baseline values. 
 
The urinary excretion of unchanged ADMA decreased at day 2 post-op, 
coinciding with the nadir of plasma ADMA concentration.  At day 5, on the 
return of plasma ADMA to baseline levels, the urinary excretion of ADMA was 
higher than at baseline.  The urinary SDMA excretion was increased during the 
post-operative period, although no changes in plasma SDMA concentration 
were seen.  No direct relationship between plasma and urine ADMA 
concentrations was found, at least in the non-inflamed state, although there 
was a strong correlation between the ratios of ADMA:SDMA in urine and 
plasma.   The significant correlation between plasma and urine ADMA 
concentrations on day 2 was not replicated on any of the other post-op days, 
but occurred at the nadir of plasma ADMA concentration.  The urinary 
fractional excretions (FE) of ADMA and SDMA were very similar in absolute 
terms and strongly correlated, both in the non-inflamed state on day 0 and 
throughout the inflammatory response on the post-operative days.  The FEs of 
both ADMA and SDMA were increased on day 1 compared with baseline, and 
also at day 5. 
 
The urinary excretion of nitrate decreased during the post-operative acute 
inflammatory response, reaching a nadir on day 2, coinciding with the peak 
CRP and nadir ADMA concentrations.  This had returned to baseline levels by 






12.1  HPLC method for ADMA measurement 
 
The analytical method described in chapter 2 has been optimised and 
validated for the simultaneous measurement of arginine, homoarginine, ADMA 
and SDMA in plasma, urine and other biological fluids.  There are certain 
advantages over previously described methods.  First, the novel description of 
a non-endogenous internal standard offers the obvious advantage of increased 
precision and accuracy.  However, its major advantage lies in permitting the 
measurement of endogenous homoarginine and MMA, as these two compounds 
are the usual internal standards employed in HPLC methods for 
dimethylarginine analysis204-211.  Although having an unclear physiological role, 
it is clear that homoarginine is present in concentrations of around 5 – 6 times 
that of ADMA in human plasma, and has recently attracted interest as a 
potentially important molecule.   In normal pregnancies plasma homoarginine 
concentration increases in the latter trimesters and is associated with flow-
mediated dilatation201.  Moreover, decreased concentrations have been 
independently associated with adverse outcomes, including mortality and 
fatal strokes in patients undergoing angiography202,269, sudden cardiac death 
and heart failure in haemodialysis patients203, and mortality in patients with 
liver cirrhosis270.  Thus, the ability to measure homoarginine is likely to be of 
increasing interest.  MMA, though present in small concentrations in plasma, 
has a concentration 10 fold higher in endothelial cells51, and measurement of 
its endogenous concentrations may thus be of interest in cellular studies.  
Moreover, MMA has been used as part of an NO clamp in experimental studies, 
thus producing an artificially high concentration in plasma samples271.  The 
selection of MEA as the internal standard thus avoids the undesirability of 
utilising the endogenous compounds homoarginine and MMA for this purpose.  
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N-propyl-L-arginine (NPA) is another non-endogenous compound that has also 
been utilised in HPLC analysis of dimethylarginines209,272.  One of these 
methods employed phenyl columns209, which offer less stability and 
reproducibility than C18 columns.  During method development, the use of 
NPA on a C18 column was investigated, and it was found difficult to achieve 
separation of NPA from SDMA; moreover chromatographic separation was 
found to be sensitive to very small variations in mobile phase composition 
which also affected reproducibility.  One published method describes a 
method using NPA on a C18 column and using 4-Fluoro-7-nitro-2,1,3-
benzoxadiazole as a derivatising agent272. However, in order to achieve 
chromatographic separation a complicated gradient elution was required, as 
was maintenance of the analytical column at 40˚C.  Moreover, the run time 
was 32 minutes, which is not an improvement on the method described in this 
thesis.  It is also notable that the authors did not describe the measurement 
of arginine and homoarginine, and it is not clear, therefore, whether these 
can be reliably quantified using that method. 
 
Second, it was possible to achieve baseline resolution of all compounds of 
interest under isocratic conditions, including arginine, homoarginine, ADMA, 
SDMA, and MMA if required.  It is desirable to measure these compounds 
simultaneously given the importance of arginine and its interaction with ADMA 
in determining NO production, and the increasing interest in homoarginine.  
The inability to measure these compounds is a major drawback of ELISA.  
Although gradient elution can be utilised with programmable solvent delivery 
systems there is an advantage in the relative simplicity of an isocratic 
method.   
 
A disadvantage of the described method is the relatively long analysis time.  
Under the conditions described attempts to decrease elution times by further 
manipulating the mobile phase were found to detrimental to the resolution of 
ADMA and SDMA.  However, this could be improved by using monolithic 
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columns while retaining the advantages already discussed.  HPLC columns 
generally consist of very tightly packed silica particles, with smaller particle 
sizes used in order to decrease diffusion distances and improve performance.  
This is at the expense of increased back pressure, which is inversely 
proportional to the spaces between the particles.  Monolithic columns consist 
of a porous single piece rod, and are much more porous, allowing operation at 
higher flow rates without excessive pressure.   Teerlink has described an HPLC 
method for dimethylarginine analysis using a monolithic column, allowing 
isocratic elution and a run time of 10 minutes (albeit using MMA as the 
internal standard)212.  It should be possible to employ monolithic columns to 
the method described in this thesis; use of the internal standard would likely 
extend the run time to around 15 minutes, which is a significant 
improvement.  Another option would be to employ MMA as the internal 
standard, which was not found to be detrimental to accuracy or precision, and 
could shorten the run time to around 25 minutes. 
 
In summary, the described analytical method permits the precise and reliable 
simultaneous measurement of arginine, homoarginine, MMA, ADMA and SDMA 
in plasma, urine and biological fluids under isocratic conditions.   
 
12.2  Reference intervals for dimethylarginines and their clinical utility 
 
The sample size of 100 individuals fell slightly short of the 120 recommended 
by the International Federation of Clinical Chemistry and Laboratory Medicine 
(IFCC) which has been calculated with a view to ensuring confidence at the 
upper and lower reference limits273.  This could be considered a weakness, 
although as the group was not sub-divided and the reference intervals 
obtained were in agreement with other studies involving larger numbers of 
subjects it was not felt that this slight shortfall would unduly influence the 
results obtained.  As no significant gender-related differences were seen for 
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homoarginine, ADMA and SDMA concentrations there was felt to need to 
describe gender-specific reference intervals.  While arginine concentrations 
were overall slightly higher in males in the present study, the biological 
significance of this was not certain as other studies have shown no significant 
differences237. 
 
Blood sampling was performed under non-fasting conditions in the present 
study.  It has been shown that plasma ADMA and SDMA concentrations are not 
significantly different fasting and post-prandially, which under-pinned the 
essentially pragmatic decision to collect samples non-fasting274.  Arginine 
concentrations increase at 2 and 4 hours post-prandially, which could 
contribute some variability to the measurements obtained for this analyte274.  
However this wasn’t the main aim of the study, and in any case the arginine 
values are in broad agreement with other published values from fasting 
samples 237.  However, some caution should be exercised in ascribing 
biological significance to the apparent gender difference in arginine 
concentrations. 
 
The reference values for ADMA described here are in broad agreement with 
other well validated chromatographic methods, which seem to suggest a 
plasma ADMA concentration of around 0.50 µmol/L as close to the healthy 
population mean233,236,237.  The slightly lower mean concentration in the 
present study (0.45 µmol/L) might represent the overall average younger age 
of the cohort.  Additionally some of the published population studies 
previously mentioned contain significant numbers of individuals who are not 
as such “healthy”, for example the study of Teerlink234 in which up to a third 
of the population had impaired glucose tolerance or diabetes as well as a 
proportion with chronic kidney disease.  These conditions would be expected 




The present data fails to replicate the association of ADMA with age seen in 
other studies233,235-237.  This might be related to the size of the cohort, which 
is arguably too small to allow sub-group comparisons.  In particular the 
number of women in the post-menopausal age range was small (n = 12).  
Obtaining data from a larger number of subjects to allow sub-group 
comparisons would be required to further investigate the effects of age and 
menopausal status, although, as previously noted, the differences are small. 
 
The intra- and inter-individual components of biological variation are of 
importance in determining the spread of values and hence the likely utility of 
reference intervals in denoting abnormality or disease in an individual when a 
single measurement falls outwith the range.  In the present study the indices 
of individuality (II) for ADMA and SDMA are below the threshold of 1.4 which 
has been proposed as the ratio suggesting utility of reference intervals.  This 
is better understood graphically by examining the box plots of 
dimethylarginine concentrations encountered in the biological variation study; 
for most of the individuals studied, their range of values are entirely 
encompassed within the overall range.  This is especially true for SDMA, which 
is not surprising given its relationship to renal function.  Therefore, although 
the described reference intervals provide something of an index of 
“normality” in health, it is clear that results within or without them cannot be 
taken to indicate the absence or presence of clinically significant disease.  An 
alternative approach is to use ADMA concentrations to complement traditional 
approaches to cardiovascular risk assessment, given what has already been 
said about its relationship to risk factors and as a prognostic marker.  
However, at least at the moment, the direct clinical utility of ADMA 
measurement is uncertain, not least owing to the lack of an intervention to 





12.3  Plasma ADMA concentrations during the acute inflammatory response 
 
The major finding of the knee arthroplasty study was a rapid and significant 
decrease in plasma ADMA concentration during the early phase of the acute 
inflammatory response.  In order to assess the likely reasons for this it is 
important to consider the various factors which influence the plasma 
concentration, namely its rate of production (within cells), metabolism at its 
site of production, export from cells (via CATs), and uptake (again via CATs) 
into other organs for clearance.  Perturbations in the plasma concentration 
could, therefore, represent changes in any or all of these processes.  Broadly 
speaking, an abrupt decrease as seen in this study suggests increased 
clearance from plasma rather than a reduction in synthesis.  Previous studies 
have suggested that inflammation can stimulate DDAH-mediated ADMA 
clearance.  In one, vascular smooth muscle cells were exposed to interleukin-
1β, a key cytokine of the inflammatory response, and demonstrated an 
increase in DDAH expression and activity175.   In another, endotoxaemia in rats 
was associated with a significant increase in hepatic fractional excretion of 
ADMA (41.0 vs 27.7%)174, which it was assumed reflected metabolism.  
However, the effects of different factors on DDAH activity make the net 
effect of inflammation difficult to predict: for example, cytokines have been 
shown to induce DDAH activity, while factors such as oxidative stress, 
hyperglycaemia and NO itself have a negative effect20.  It was anticipated 
that increased DDAH-mediated catabolism would lead to an increase in urine 
DMA excretion.  In fact, urine DMA excretion remained unchanged during the 
first 4 post-operative days, while the decrease in plasma ADMA concentration 
was evident as early as 12 hours post-op.  Once produced DMA is expected to 
appear rapidly in urine given its short elimination half-life of around 7 hours 
and almost complete excretion of an orally administered dose within 24 
hours249.  The results, therefore, suggest that increased DDAH-mediated 
catabolism was not responsible for the described changes in plasma ADMA 
concentration.  An increase in DMA excretion was finally seen by day 5, 
coinciding with the return of plasma concentration to baseline levels.   
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In the absence of clear evidence for increased metabolism, it could be 
hypothesised that the decrease in plasma ADMA concentration reflects 
increased redistribution intracellularly.  The data for urine ADMA excretion 
could provide support for this: although no direct correlation between plasma 
and urine ADMA concentrations was found, there was a significant decrease in 
urine ADMA excretion on day 2, and a significant increase on day 5, in 
absolute terms.  The baseline (day 0) ADMA concentrations were very similar 
to values of 3.4 and 4.1 µmol/mmol creatinine as reported by others in 
healthy non-inflamed individuals221,275.   While SDMA is excreted solely by the 
kidney, only a relatively small fraction of ADMA is excreted unchanged.  It is 
assumed that the urinary excretion of ADMA, in absolute terms, is related to 
the amount presented to the kidney, and by GFR.  This assumption is perhaps 
justified by the finding urinary fractional excretion (FE) rates of (unchanged) 
ADMA and SDMA which are numerically very similar and strongly correlated 
throughout the study period.  Although there is an abrupt and transient 
increase in the FEs of both ADMA and SDMA on day 1, this is unlikely to 
account for the decrease in plasma ADMA concentration, given the absolute 
reduction in urine ADMA concentration, and the lack of similar changes in 
plasma SDMA concentration.  Therefore, the described changes in urinary 
ADMA excretion are likely a simple reflection of a reduction in the circulating 
ADMA pool on day 2 and a subsequent increase on day 5.  It is also notable 
that the correlation between urinary DMA and ADMA concentrations in the 
baseline, non-inflamed, state was lost during the inflammatory response, 
further suggesting a change in the distribution of ADMA between plasma, 
which is the source of urinary ADMA, and cells, which are the source of DMA.  
Finally, a decrease in urinary nitrate excretion on day 2 suggested a reduction 
in NOS production, which could also be consistent with increased cellular 
partitioning; certainly had a reduction in cellular ADMA concentration 
occurred, an increase in NOS activity, if anything, might have been 




There have been very few studies relating plasma and intracellular 
concentrations of ADMA, most published data focussing on plasma 
concentrations with the implicit assumption that they reflect concentrations 
intracellularly.  However, it is clear that intracellular ADMA concentrations 
can be several times higher than plasma in a variety of tissues, and can 
increase in response to injury and inflammation.  In a rabbit model of critical 
illness, injury was associated with higher concentrations of ADMA in liver 
compared with healthy control animals276; this was especially true in 
hyperglycaemic animals who had lower liver activities of DDAH.  In this same 
model concentrations of SDMA correlated with concentrations in kidney, liver 
and myocardium, with no such direct relationship seen between tissue and 
plasma concentrations of ADMA276.  Further analysis on pooled data from this 
same model showed correlations between ADMA concentrations in various 
tissues, but no strong relationships between ADMA concentrations in plasma 
and kidney, skeletal muscle or myocardium; plasma and liver ADMA were 
correlated, but this lost significance in a multivariable model277.  In this 
model, it is also interesting to note that DDAH activities are poorly correlated 
with intracellular ADMA concentrations, but are a much stronger determinant 
of plasma ADMA concentration, activities in liver, kidney and muscle together 
accounting for around 50% of the variation in plasma ADMA277.  Further 
insights have been gained from studies in models of lung injury.  Sheep given 
a burn injury from smoke inhalation had significantly increased lung tissue 
concentrations of ADMA 3 weeks following the injury, associated with a 
significant reduction in DDAH-2 activity;  DDAH-1 activity was significantly 
increased, making it uncertain which isoform of DDAH is of greater 
importance278.  Interestingly, in this same model the plasma arginine 
concentration decreased rapidly following the injury, returning to baseline 
levels about one week following the injury, similar to the findings in the 
present study; unfortunately plasma concentrations of ADMA and SDMA were 
not reported278.  In a mouse of model of endotoxin-induced lung injury similar 
findings were reported; as early as 2 hours post-injury a significant increase in 
lung ADMA occurred (12.13 vs 7.53 nmol/gww), with a further increase at 12 
hours (19.10 nmol/gww)279.  In this study DDAH-1 and DDAH-2 protein 
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expression was unchanged, but a significant decrease in DDAH activity was 
measured; moreover, at 12 hours iNOS expression and nitric oxide metabolites 
were increased279.  Again, plasma dimethylarginine concentrations were not 
reported.  Even in the basal, non-inflamed, state lung tissue contains 
significant quantities of protein-incorporated ADMA and free ADMA 
concentrations similar to that in heart, but significantly lower than liver and 
kidney280.  Interestingly, both mice and humans display similar ADMA:SDMA 
ratios in plasma and fluid from bronchoalveolar lavage, suggesting similar 
ratios intra- and extracellularly280.  This study also demonstrated significantly 
greater expression of DDAH-2 than DDAH-1 in lung tissue. 
 
While the studies described in the foregoing paragraph suggest that 
intracellular concentrations of ADMA can increase significantly during tissue 
injury and inflammation, the relationship between plasma and intracellular 
concentrations is not clear.  However, it is known that endothelial cells in the 
basal state contain up to 10 times the ADMA concentration found in 
plasma34,281.  Furthermore, vascular injury results in an almost 4-fold increase 
in the intracellular concentrations of ADMA and MMA, sufficient to cause eNOS 
uncoupling and impairment of vascular relaxation281.  Stimulated peripheral 
blood mononuclear cells generate a significant increase in ADMA 
concentration, something which is inhibited by the anti-inflammatory 
compound salicylic acid281.   
 
The evidence from the studies discussed suggests that DDAH inhibition in 
inflammatory states could lead to intracellular ADMA accumulation.  However, 
transport through system y+ CATs is another potential mechanism for this 
concentration.  CATs permit bidirectional movement of basic amino acids into 
and out of cells.  Methylarginines are good substrates for CATs, with ADMA, 
MMA and SDMA all capable of transport in competition with arginine52.  
Therefore, in addition to inhibition of NOS, methylarginines, including SDMA, 
can affect NOS activity by reducing availability of arginine.  CATs are widely 
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distributed although as such do not lead to equilibrium between the intra- and 
extracellular compartments163.  They exhibit the phenomenon of trans-
stimulation in which high a concentration on one side of the transporter 
stimulates transport266,282.  There is distinct tissue distribution, with CAT-1 
expressed in virtually all tissues with the exception of the liver; CAT-2A, in 
contrast, is found mainly in the liver266,282.  CAT-1 displays a Km for arginine 
of around 100 – 150 µM, while CAT-2A has a 10-fold lower affinity than CAT-
1266,282.  This may serve to ensure preferential uptake of arginine by cells 
expressing eNOS, rather than by the liver for degradation by arginase.  
Indeed, the co-localisation of CAT-1 and eNOS may ensure the efficient 
delivery of arginine to the enzyme, and extracellular arginine concentrations 
are probably more important than intracellular concentrations in determining 
NOS activity in endothelial cells283.  However, this also ensures access to eNOS 
by ADMA155. The demonstration of DDAH-2 in the cytoplasm and apical vesicles 
places all of the key players, namely NOS, DDAH and CATs in close 
proximity14.  CAT-2B are inducible by inflammatory cytokines and are often 
found in tissues expressing iNOS, and have lower substrate affinity than CAT-
1190,266,282,284.   Knockout studies have shown that CAT-1 knockout is lethal, 
while the effect of CAT-2 knockout in mice is to reduce basal NO production 
by iNOS which leads to lung inflammation in the absence of pathological 
stimuli, related to reduced NO production in alveolar macrophages285.  Other 
stimuli for CAT expression include tissue growth and repair, insulin and 
starvation, while oxidative stress can have an inhibitory effect266.  There is 
evidence in rats that CAT-1 expression is also induced by inflammation in the 
kidney and lung in particular, and that this induction is rapid, within hours284.  
Human embryonic kidney cells over-expressing CAT-1 were found to be 
capable of significant increases in ADMA and arginine uptake, which amounted 
to an almost 9-fold increase in ADMA transport285.  These studies confirmed 
the competitive nature of such transport, showing inhibition of ADMA uptake 
at high, but physiological, concentrations of arginine.  It was also shown that 
these cells demonstrated increased efflux of arginine and ADMA from cells 
into transport buffer not containing them285.    The role of CATs is highlighted 
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by experimental studies showing a rapid removal of arginine from the 
circulation following infusion, and the rapid clearance of infused ADMA which 
had a mean plasma half-life of 24 minutes in one human study42,287.  The 
effect of insulin is also worthy of consideration in relation to the changes seen 
in the present study.  Patients post knee arthroplasty demonstrated an insulin 
resistant state and a significant increase in plasma insulin as early as day 1 
post-op.  Insulin infusions, into both healthy subjects and type 1 diabetics, 
lead to a rapid and significant decrease in plasma ADMA and arginine 
concentrations with much less of an effect on SDMA195,288.  Two further studies 
in type 1 diabetics showed lower ADMA concentrations compared with healthy 
controls, with one showing an increase in NO metabolites, and the other 
showing no relationship between plasma ADMA concentration and forearm 
blood flow289,290. Furthermore, hormone treatment in male to female 
transsexuals was associated with a reduction in plasma ADMA concentration, 
with speculation that reduced peripheral insulin sensitivity and consequent 
hyperinsulinaemia could be responsible for the effect291.  The observed 
reductions in ADMA concentrations in critically ill patients receiving intensive 
insulin therapy has been proposed to be due to preservation of DDAH activity; 
however, CAT-mediated uptake could potentially be involved193.  Thus, in the 
present study stimulation of CAT-mediated transport by inflammation and 
insulin remain possible contributory mechanisms for the observed changes in 
plasma ADMA concentration.  However, the lack of similar changes in SDMA 
concentration is more difficult to explain, given that ADMA and SDMA should 
be equally good substrates for CATs52.  It would also be difficult to anticipate 
this effect in isolation, as the hyperglycaemia and oxidative stress would 
likely also have an inhibitory effect on DDAH and thus ADMA metabolism30. 
 
There have been relatively few human studies examining plasma 
dimethylarginines in acute inflammation, and none documenting a sharp 
decrease from a non-inflamed baseline.  It has already been stated that high 
ADMA concentrations are associated with adverse outcomes in critical illness 
and may be related to multiple organ dysfunction.  In these studies, the 
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effects of organ failure themselves are likely to a dominant factor in 
increasing ADMA concentrations, given the importance of liver and kidney 
function in particular for ADMA metabolism.  However, the aim of the current 
study was to examine the effect of inflammation itself in the absence of 
significant organ dysfunction.  One small study of patients with bacterial 
infections demonstrated an increase in plasma ADMA concentration on 
resolution of infection with no changes in SDMA, prompting the authors to 
speculate increased DDAH activity as a possible cause188.  Endotoxaemia in 
humans led to a reduction in plasma arginine concentration and a reduction in 
the arginine:ADMA ratio, although the study period was only 3.5 hours, 
possibly too early to see changes in plasma ADMA concentration; however, the 
reduction in arginine concentration suggests acute uptake or consumption186.    
Further human studies have shown increases in ADMA concentrations during 
the recovery from sepsis, but not in septic shock182, and low arginine 
concentrations in critically ill children which increase during recovery292.  In 
another study patients undergoing abdominal surgery demonstrated a modest 
reduction in plasma ADMA concentration on day 1 post-op, compared with 
patients undergoing major hepatectomy who showed no change17.  These 
findings are largely consistent with those in the present study.   
 
One further possibility to consider is that of metabolic pathways other than 
DDAH for ADMA degradation.  It has been shown that the enzyme alanine-
glyoxylate aminotransferase 2 (AGXT2) metabolises ADMA in a mouse model of 
over-expression using an adenoviral expression vector293.  Conversely, 
pharmacological inhibition of AGXT2 in mice was associated with increased 
concentrations of both ADMA and SDMA294.  A further study in knockout mice 
demonstrated increased ADMA concentrations and hypertension295.  However, 
the relevance of this pathway in man is uncertain, with DDAH-mediated 
catabolism likely to account for the majority of enzymatic ADMA 
clearance22,296.  However, evaluation of this pathway in different physiological 
states, including inflammation would be of value in excluding significant non-
DDAH mediated catabolism of ADMA in explaining the results from the present 
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study.  Measurement of its metabolic product α-keto dimethylguanidino-
valeric acid (DMGV) in urine has been successfully undertaken, providing a 
possible way of assessing significant changes in its metabolic activity297. 
 
To summarise, acute inflammation is associated with a rapid, significant and 
transient reduction in plasma ADMA concentration.  While the influence of 
DDAH on plasma ADMA concentration is not in doubt, the results from the 
present study mitigate against a significant increase in DDAH activity, at least 
initially.  Neither was increased renal excretion implicated, based on urine 
concentrations which were felt to simply reflect the ADMA concentration.  
The likeliest explanation is increased compartmentalisation intracellularly 
mediated by increased CAT uptake.  No evidence was found to suggest 
increased accumulation within erythrocytes.  A decrease in urine nitrate, 
reflecting reduced NOS activity, is consistent with this hypothesis.  The later 
increase in DMA excretion is likely to represent remobilisation of the 
intracellular pool and transport to quantitatively important sites of DDAH 
metabolism: this does not necessarily mean that DDAH activity was increased 
per se, as the Km of DDAH means that increased amounts of ADMA presented 
to the enzyme will be rapidly metabolised.  Certainly it is clear that in the 
inflamed state the plasma concentration is unlikely to be representative of 
the intracellular concentration.  The differential responses of the 
dimethylarginines described in the present study raises the possibility of a 
physiological role for ADMA in regulating NOS activity during the early phase 
of acute inflammation.  
 
12.4  Suggestions for further work 
 
A large body of work, spanning over 20 years, has been produced providing 
strong evidence for ADMA as an endogenous inhibitor of NOS, and thus a 
molecule important in the pathogenesis of disease states characterised by 
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impairment of NO-mediated responses.  This has included large 
epidemiological and prospective observational studies establishing the 
independent prognostic value of ADMA for cardiovascular events and 
mortality, and, increasingly, in the outcome of critically ill patients.  Despite 
this work, however, fundamental questions remain regarding the basic biology 
of ADMA.  Is it simply an “innocent” by-product of protein metabolism which 
acquires relevance only when some other condition leads to impairment of its 
metabolism, or is it part of a regulatory system controlling the production of 
NO under certain physiological conditions such as the inflammatory response?  
This question is of particular interest as excessive NO production has been 
proposed to be deleterious and a potential contributor to multi-organ 
dysfunction in critical illness.  This latter proposal has led to trials of the 
related NOS inhibitor, MMA, in this patient group, unfortunately with adverse 
outcomes.  If the work in this thesis points to intracellular 
compartmentalisation of ADMA during the acute inflammatory response, it 
may be speculated that this could potentially be associated with something 
approaching isoform-specific regulation of NOS, depending on the 
predominant sites of accumulation.  It is suggested that this should be a key 
question for future research, and the central part of this is the relationship 
between extracellular, as exemplified by plasma, concentrations and those 
intracellularly, in various tissues.  There is precious little published on this 
relationship, although that which exists suggests that intracellular 
concentrations are increased by inflammatory stimuli, although how this 
relates to the overall distribution of ADMA in these states is not known.  
Furthermore, most of the published work is in animal models, thus further 
work in humans is required, although the relative difficulty in obtaining 
relevant tissue samples, especially in a study involving serial measurements, 
is acknowledged.  A recent publication reporting dimethlyarginine 
concentrations in peripheral blood mononuclear cells298 – albeit only in 
healthy non-inflamed subjects – suggests a way forward, as these could be 
feasibly assessed serially, perhaps using a model similar to that described in 
this thesis.  These cells would be more relevant than erythrocytes as they 
contain the necessary cellular machinery to transport and metabolise ADMA, 
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i.e. CATs and DDAH, as well as the inducible isoform of NOS.  This work will 
be important in elevating ADMA from its status as a marker of disease to that 
of mediator, and thus its “life-cycle” from production to metabolism as a 
possible therapeutic target. 
 
Homoarginine is a relative new-comer to the arginine field of research, in 
terms of possible biological interest in humans.  Much fundamental knowledge 
regarding its basic biology, i.e. origin, metabolism and biological effects, is 
lacking as its low concentration relative to arginine has seemingly hitherto 
rendered it of little interest.  However, a few recently published studies 
suggesting a predictive role for mortality following cardiovascular events and 
an association with blood pressure and vascular haemodynamics have 
suggested it worthy of further study.  This should initially focus on its origin in 
humans and, along the lines suggested for ADMA, proceed to study of it intra 
and extracellular distribution and the factors determining this.
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 Appendix 1 
Results from reference subjects (n = 100) 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































*Some CRPs reported as < 6.0 were measured on a less sensitive CRP assay; 




Demographic information, means, SD and resultant CVI for subjects 
enrolled in biological variation study 
Subject 1: F Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 102 1.40 0.40 0.36 
SD 17.83 0.21 0.03 0.02 
CVI, % 17.1 14.7 7.0 3.9 
 
Subject 2: F Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 103 0.94 0.45 0.38 
SD 19.29 0.18 0.06 0.03 
CVI, % 17.4 19.2 12.5 5.8 
 
Subject 3: M Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 68 1.92 0.40 0.44 
SD 11.13 0.21 0.03 0.03 








Subject 4: M Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 77 2.35 0.47 0.40 
SD 17.72 0.30 0.03 0.03 
CVI, % 22.8 12.3 6.4 6.1 
 
Subject 5: F Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 90 0.97 0.49 0.41 
SD 19.9 0.14 0.03 0.03 
CVI, % 21.9 13.9 6.4 6.6 
 
Subject 6: M Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 88 2.50 0.42 0.37 
SD 10.2 0.23 0.02 0.02 
CVI, % 11.1 8.9 5.1 5.0 
 
Subject 7: F Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 84 1.46 0.52 0.44 
SD 16.9 0.24 0.04 0.03 





Subject 8: M Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 100 1.03 0.54 0.49 
SD 17.64 0.16 0.05 0.03 
CVI, % 17.3 15.5 9.8 6.2 
 
Subject 9: F Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 80 2.32 0.44 0.34 
SD 9.22 0.42 0.03 0.02 
CVI, % 11.1 17.7 6.6 3.9 
 
Subject 10: M Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 78 3.19 0.49 0.36 
SD 9.33 0.52 0.03 0.02 
CVI, % 11.6 16.0 6.0 5.6 
 
Subject 11: F Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 83 2.33 0.46 0.37 
SD 12.97 0.37 0.03 0.02 





Subject 12: M Arginine Homoarginine ADMA SDMA 
Mean, µmol/L 89 1.73 0.44 0.26 
SD 10.75 0.22 0.03 0.02 






Patient information sheet and consent form 
 
1.   Study title 
 
Measurement of cellular oxidative stress following elective orthopaedic 
surgery. 
How does having a knee joint replacement effect the concentration of 
particular molecules in the blood? 
 
2.   Invitation paragraph 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it 
will involve.  Please take time to read the following information carefully and 
discuss it with others if you wish.  Ask us if there is anything that is not clear 
or if you would like more information.  Take time to decide whether or not 
you wish to take part. 
Thank you for reading this. 
 
 
3. What is the purpose of the study? 
 
This study’s purpose is to give a better understanding of how the human body 
reacts to inflammation. Inflammation is the normal response to any physical 
insult. The aim of this study is to measure the concentration in the blood of 
products of cellular metabolism that may change during inflammation. 
Increasing our knowledge in this area may help us to understand why 
individual patients respond differently to similar injuries and disease. Elective 
knee joint replacement provides a good model to measure this response in 
normal adults. The data from this study is essential to allow us to measure 
and understand the same variables in seriously ill hospital patients. 
 
4. Why have I been chosen? 
You have been chosen because you are about to undergo a knee joint 




5.   Do I have to take part? 
It is up to you to decide whether or not to take part.  A member of the 
research team will meet with you to describe the study and go through this 
information sheet with you. If you do decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form. You are 
still free to withdraw at any time and without giving a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
 
6.  What will happen to me if I take part? 
If you decide to take part, you will have additional blood and urine samples 
collected. Using a needle and syringe we will take 15 millilitres (about an egg 
cupful) of blood each time usually from your arm. The first blood sample will 
be collected in the anaesthetic room, just before the start of your operation. 
Further blood samples will be collected approximately 6 and 12 hours after 
the start of your operation and on each morning after the operation for up to 
5 days or until you go home, if sooner. We will also collect a urine sample 
from you each morning during your hospital stay. A final blood sample will be 
collected when you return to the orthopaedic clinic approximately 6 weeks 
later. 
 
Where possible, to minimise the number of times that blood is taken from 
you, samples for this research will be collected with the blood samples that 
are taken as part of your routine care in hospital. 
 
You will only participate in this study during your normal hospital stay. 
Participation in this study will neither prolong your hospital stay nor require 
you to attend the hospital for the purpose of the study alone. 
  
In total you will be involved in the study for approximately 6 weeks during 






7.   What do I have to do? 
After your operation, morning blood samples will be collected before 
breakfast. We  require that you don’t eat from midnight until the blood 
sample is taken around 7am. You would be allowed to drink water freely 
throughout the night. We would also ask you to provide a urine sample each 
morning that you are in hospital. There are no other lifestyle restrictions 
other than those explained at the time of surgery.  You can carry out your 
daily activities as normal and take all regular medication. 
8.   What is the drug or procedure that is being tested? 
There is no drug being tested and the procedures used are performed 
routinely and are safe. 
 
9.   What are the alternatives for diagnosis or treatment? 
As your operation is not affected by the study, there are no alternatives for 
treatment. 
 
10.  What are the side effects of taking part? 
There are no specific side effects of taking part in the study. The operation 
performed is the same whether you are in the trial or not. 
 
11.  What are the possible disadvantages and risks of taking part? 
Taking the blood samples may cause some minor brief discomfort. In addition 
there is a small risk of bruising and local irritation. 
Your knee replacement operation itself, has risks and these will be explained 
to you when you consent for it. The operation performed will be the same as 
if you were not in the trial. 
Very rarely when performing a routine operation or test we find evidence of a 
disease or condition that is not expected and is causing no symptoms at 
present.  If this occurs we would do what we felt to be in your best interests 





12.  What are the possible benefits of taking part? 
There is no particular benefit to you, over and above that of the operation 
itself. 
 
13.    What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about what is being studied.  If this happens, your research doctor 
will tell you about it and discuss with you whether you want to continue in the 
study.  If you decide to withdraw your research doctor will make 
arrangements for your care to continue. If you decide to continue in the study 
you will be asked to sign an updated consent form. 
Also, on receiving new information your research doctor might consider it to 
be in your best interests to withdraw you from the study.  He/she will explain 
the reasons and arrange for your care to continue. 
 
14.  What will happen to the samples I give? 
Blood and urine samples collected from you will stored and undergo 
laboratory analysis at Glasgow Royal Infirmary. No genetic tests are being 
done. Your blood and urine samples would be labelled with a unique study 
number allocated to you so that they cannot be identified by laboratory staff.  
 
15.  What will happen if I don’t want to carry on in the study?  
You can withdraw from the study at any time if you wish, and without giving a 
reason. Information that has already been collected may still be used. Any 
stored blood samples that can still be identified as yours will be destroyed if 
you wish. 
 
16.  What happens when the research study stops? 
When the study stops, patients will attend the hospital for the same routine 
follow-up as those patients who were not in the study. Any remaining blood 




17.    What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone's negligence, 
then you may have grounds for a legal action but you may have to pay for it.  
Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms may be 
available to you. 
 
18.  Will my taking part in this study be kept confidential? 
If you join the study, some parts of your medical records will be looked at by 
a member of the research team who may or may not be directly involved in 
your clinical care. All will have a duty of confidentiality to you as a research 
participant. All information which is collected about you during the course of 
the research will be kept strictly confidential and any information about you 
which leaves the hospital will have your name and address removed so that 
you cannot be recognised from it. 
 
Your G.P will also be made aware of your participation in the study. 
 
19.  What will happen to the results of the research study? 
The results of the study will be analysed and subsequently published in a 
scientific journal.  You will not be identified in any report/publication. 
If you wish to know the results of the study, please contact me through the 
department of anaesthesia. (0141 211 2069.) 
 
20.  Who has reviewed the study? 







21.   Contact for Further Information 
My name is David Reid.  If you require any further information, I can be 
contacted in Gartnavel General Hospital Department of Anaesthesia on 0141 
211 2069. 
Professor John Kinsella is the Consultant in charge of the trial and he can be 
contacted via his secretary on 0141 211 4625. 
Thank you for taking the time to read this information and for agreeing to 
take part in the study. 
 
You will be given a copy of the information sheet to keep and a signed 
consent form. 
 
5th May 2008 
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Patient Identification Number for this study: 
 
CONSENT FORM  
 
Title of Project: Measurement of cellular oxidative stress following elective 
orthopaedic surgery. 
 
Name of Researcher:  Dr David Reid 
 
1. I confirm that I have read and understand the information sheet 
dated............................ (version............ ) for the above study and 
have had the opportunity to ask questions.          
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals or from regulatory authorities where it is relevant 
to my taking part in research.  I give permission for these individuals to 
have access to my records. 
4.   I agree to my GP being informed of my participation in the study. 
5.   I agree to take part in the above study.    
   
     
 
___________________  ____________         ____________________ 
Name of patient   Date   Signature 
 
 
___________________  _____________     _____________________ 
Name of person taking  Date   Signature 
consent 
 












Demographic details and details of blood transfusion and available 
specimens for patients enrolled in knee replacement study. 
Subject Sex Age Diabetes Blood transfusion Available specimens* 
1 F 75 N N D0 – D4, 3M 
2 F 74 N N D0 – D4, D5, 3M 
3 M 62 Y N D0 – D4, D5, 3M 
4 F 68 N N D0 – D4, D5 
5 F 77 N Day 3 D0 – D4, D5, 3M 
6 M 73 N N D0 – D4, D5, 3M 
7 F 69 N N D0 – D4, D5, 3M 
8 M 73 N N D0 – D4, 3M 
9 F 78 N Day 2 D0 – D4, D5, 3M 
10 F 69 N Day 2 D0 – D4, D5, 3M 
11 F 71 N N D0 – D4, D5, 3M 
12 F 79 N Day 2 D0 – D4, D5, 3M 
13 F 78 N N D0 – D4, D5 
14 F 75 N Day 2 D0 – D4, D5, 3M 
15 F 64 N N D0 – D4, D5, 3M 
16 M 74 N Day 2 D0 – D4, D5, 3M 
17 M 65 Y N D0 – D4, D5, 3M 
18 M 79 Y N D0 – D4, D5, 3M 
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19 F 71 N N D0 – D4, 3M 
20 F 81 Y Day 2 D0 – D4, D5 
21 M 62 N N D0 – D4 
22 M 72 Y N D0 – D4, 3M 
23 M 68 Y N D0 – D4, D5, 3M 
24 F 55 N N D0 – D4 
25 F 68 N N D0 – D4, D5, 3M 
26 F 74 N N D0 – D4, D5, 3M 
27 M 78 N N D0 – D4, D5, 3M 
28 F 72 N N D0 – D4, D5 
29 F 55 Y N D0 – D4, D5 
30 M 73 N N D0 – D4, D5, 3M 
31 M 65 N N D0 – D4, D5, 3M 
32 M 64 Y N D0 – D4, 3M 
33 F 66 N N D0 – D4 
34 F 59 Y N D0 – D4, 3M 
35 F 61 N N D0 – D4 
36 M 72 N N D0 – D4, D5 
37 F 63 N N D0 – D4, D5 
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